About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
16264 genotypes with 37285 annotations displayed of selected term and subterms
Searched Term: homeostasis/metabolism phenotype
Allelic Composition
(Genetic Background)
Annotated Term Reference
1500009L16Rikem1(IMPC)Mbp/1500009L16Rikem1(IMPC)Mbp
(C57BL/6NCrl-1500009L16Rikem1(IMPC)Mbp/Mmucd)
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating calcium level J:211773
increased circulating serum albumin level J:211773
increased circulating total protein level J:211773
1700016H13Rikem1(IMPC)Bay/1700016H13Rikem1(IMPC)Bay
(C57BL/6N-1700016H13Rikem1(IMPC)Bay/BayMmucd)
decreased body temperature J:211773
1700016L21RikTg(Itgax-DTR/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-DTR/EGFP)57Lan/J)
decreased circulating interferon-gamma level J:96123
decreased circulating interleukin-12 level J:96123
1700016L21RikTg(Itgax-DTR/EGFP)57Lan/0
(C.FVB-1700016L21RikTg(Itgax-DTR/EGFP)57Lan/J)
decreased circulating interferon-gamma level J:96123
decreased circulating interleukin-12 level J:96123
1700016L21RikTg(Itgax-DTR/EGFP)57Lan/0
(involves: FVB/N)
decreased physiological sensitivity to xenobiotic J:193548
1700016L21RikTg(Itgax-DTR/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-DTR/EGFP)57Lan)
abnormal circulating cytokine level J:194800
1700025G04Rikem1(IMPC)Mbp/1700025G04Rikem1(IMPC)Mbp
(C57BL/6NCrl-1700025G04Rikem1(IMPC)Mbp/Mmucd)
increased circulating bilirubin level J:211773
1700028K03Rikem1Jzc/1700028K03Rikem1Jzc
(C57BL/6-1700028K03Rikem1Jzc)
abnormal double-strand DNA break repair J:285969
1700034E13Rikem1(IMPC)Mbp/1700034E13Rikem1(IMPC)Mbp
(C57BL/6NCrl-1700034E13Rikem1(IMPC)Mbp/Mmucd)
increased circulating alkaline phosphatase level J:211773
1700123O20Riktm1a(EUCOMM)Wtsi/1700123O20Riktm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd 1700123O20Riktm1a(EUCOMM)Wtsi/WtsiFlmg)
increased circulating iron level J:211773
1700125H20Riktm1b(EUCOMM)Wtsi/1700125H20Riktm1b(EUCOMM)Wtsi
(C57BL/6N-1700125H20Riktm1b(EUCOMM)Wtsi/Bay)
increased circulating calcium level J:211773
2210010C04Riktm1.1Satom/2210010C04Rik+
(B6(FVB)-2210010C04Riktm1.1Satom)
decreased circulating amylase level J:267764
homeostasis/metabolism phenotype J:267764
2210010C04Riktm1b(KOMP)Wtsi/2210010C04Riktm1b(KOMP)Wtsi
(C57BL/6N-2210010C04Riktm1b(KOMP)Wtsi/Bay)
decreased circulating alanine transaminase level J:211773
2210408I21Riktm1b(EUCOMM)Wtsi/2210408I21Riktm1b(EUCOMM)Wtsi
(C57BL/6N-2210408I21Riktm1b(EUCOMM)Wtsi/Tcp)
impaired glucose tolerance J:211773
increased circulating triglyceride level J:211773
2500002B13RikGt(Ayu21-T167)Imeg/2500002B13RikGt(Ayu21-T167)Imeg
(involves: C57BL/6NCrlj * CBA/JNCrlj)
increased response of heart to induced stress J:311513
2500002B13Riktm1(CAG-2500002B13Rik)Yo/2500002B13Rik+
(involves: C57BL/6NCrlj * CBA/JNCrlj)
decreased response of heart to induced stress J:311513
2610005L07RikGt(ROSA)73Sor/2610005L07RikGt(ROSA)73Sor
Pdgfratm1Sor/Pdgfra+

(either: (involves: 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6))
decreased circulating estradiol level J:142042
2610318N02Riktm1b(EUCOMM)Wtsi/2610318N02Riktm1b(EUCOMM)Wtsi
(C57BL/6N-2610318N02Riktm1b(EUCOMM)Wtsi/Wtsi)
decreased circulating creatinine level J:211773
2700049A03Riktm1.2Arte/2700049A03Riktm1.2Arte
(either: (involves: C57BL/6NTac) or (involves: C57BL/6NTac * CD-1))
pericardial edema J:175541
2700097O09Riktm1.1(KOMP)Vlcg/2700097O09Riktm1.1(KOMP)Vlcg
(C57BL/6N-2700097O09Riktm1.1(KOMP)Vlcg/MbpMmucd)
increased circulating alkaline phosphatase level J:211773
increased circulating calcium level J:211773
3425401B19Rikem2(IMPC)Ccpcz/3425401B19Rikem2(IMPC)Ccpcz
(C57BL/6NCrl-3425401B19Rikem2(IMPC)Ccpcz/Ph)
decreased circulating potassium level J:211773
4833411C07Rikem1Cecad/4833411C07Rikem1Cecad
(C57BL/6N-4833411C07Rikem1Cecad)
impaired glucose tolerance J:285483
increased circulating glucose level J:285483
insulin resistance J:285483
4833420G17Rikem1(IMPC)Mbp/4833420G17Rikem1(IMPC)Mbp
(C57BL/6NCrl-4833420G17Rikem1(IMPC)Mbp/Mmucd)
increased circulating bilirubin level J:211773
4930404H24Riktm1a(KOMP)Wtsi/4930404H24Riktm1a(KOMP)Wtsi
(C57BL/6N-4930404H24Riktm1a(KOMP)Wtsi/Wtsi)
decreased circulating serum albumin level J:211773
4930505A04Riktm1b(KOMP)Wtsi/4930505A04Riktm1b(KOMP)Wtsi
(C57BL/6N-4930505A04Riktm1b(KOMP)Wtsi/Bay)
decreased circulating alkaline phosphatase level J:211773
decreased circulating glucose level J:211773
4930563E22Riktm1.1(KOMP)Vlcg/4930563E22Riktm1.1(KOMP)Vlcg
(B6N(Cg)-4930563E22Riktm1.1(KOMP)Vlcg/J)
decreased fasting circulating glucose level J:211773
4931414P19Rikem1Lych/4931414P19Rikem1Lych
(involves: C57BL/6)
decreased thyroxine level J:275266
decreased triiodothyronine level J:275266
increased circulating thyroid-stimulating hormone level J:275266
4931429L15Riktm1a(EUCOMM)Wtsi/4931429L15Riktm1a(EUCOMM)Wtsi
(C57BL/6N-4931429L15Riktm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating calcium level J:211773
increased blood urea nitrogen level J:211773
4933402J07Rikem1(IMPC)J/4933402J07Rikem1(IMPC)J
(C57BL/6NJ-4933402J07Rikem1(IMPC)J/Mmjax)
improved glucose tolerance J:211773
4933402N03Riktm2a(KOMP)Wtsi/4933402N03Riktm2a(KOMP)Wtsi
(C57BL/6N-4933402N03Riktm2a(KOMP)Wtsi/Wtsi)
decreased circulating fructosamine level J:211773
increased circulating calcium level J:211773
4933428G20Riktm1.1(KOMP)Vlcg/4933428G20Riktm1.1(KOMP)Vlcg
(C57BL/6N-4933428G20Riktm1.1(KOMP)Vlcg/MbpMmucd)
increased circulating alanine transaminase level J:211773
4933430I17Riktm1b(EUCOMM)Wtsi/4933430I17Riktm1b(EUCOMM)Wtsi
(C57BL/6N-4933430I17Riktm1b(EUCOMM)Wtsi/Ics)
increased circulating alanine transaminase level J:211773
4933434E20Riktm1a(EUCOMM)Wtsi/4933434E20Rik+
(C57BL/6N-4933434E20Riktm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating cholesterol level J:211773
decreased circulating fructosamine level J:211773
decreased circulating HDL cholesterol level J:211773
decreased circulating serum albumin level J:211773
increased circulating alanine transaminase level J:211773
4933434E20Riktm1a(EUCOMM)Wtsi/4933434E20Riktm1a(EUCOMM)Wtsi
(C57BL/6N-4933434E20Riktm1a(EUCOMM)Wtsi/Wtsi)
subcutaneous edema J:239583
7630403G23RikTg(Th-cre)1Tmd/7630403G23Rik+
Trpc5tm1.1Mfre/Trpc5tm1.1Mfre

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N * SJL)
decreased circulating luteinizing hormone level J:277600
decreased circulating prolactin level J:277600
9030622O22Rikem1Eem/9030622O22Rikem1Eem
(involves: C57BL/6 * CD-1)
increased susceptibility to injury J:284174
9530003J23Riktm1(KOMP)Vlcg/9530003J23Riktm1(KOMP)Vlcg
(C57BL/6N-9530003J23Riktm1(KOMP)Vlcg/MbpMmucd)
increased circulating alanine transaminase level J:211773
increased circulating aspartate transaminase level J:211773
a/a
Hps6ru/Hps6ru

(B6.Cg-Hps6ru)
decreased platelet serotonin level J:7327, J:29748
increased bleeding time J:7327
a/a
Rab27aash/Rab27aash

(involves: C3H/HeSnJ * C57BL/6J)
decreased platelet serotonin level J:77395
increased bleeding time J:77395
a/a
Rmi1Gt(pUHachi)0283Imeg/Rmi1+

(involves: C57BL/6 * KK)
decreased circulating glucose level J:168271
improved glucose tolerance J:168271
a/Ay
Guq1KK/Guq1KK

(involves: C57BL/6J * KK-Ay)
increased urine glucose level J:131439
a/Ay
Guq2C57BL/6J/Guq2C57BL/6J

(involves: C57BL/6J * KK-Ay)
increased urine glucose level J:131439
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
Ak2em1.1Dze/Ak2em1.1Dze

(involves: 129 * C57BL/6 * FVB/N)
abnormal metabolism J:305579
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
Tg(CAG-cat,-Dusp14)4Lyg/0

(involves: C57BL/6J * FVB/N)
decreased response of heart to induced stress J:263251
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
Tg(Myh6-2A)#Know/0

(involves: BALB/c * C57BL/6 * FVB/N)
ascites J:128060
pleural effusion J:128060
A1cftm1c(EUCOMM)Hmgu/A1cftm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: C57BL/6N * DBA)
abnormal blood homeostasis J:281365
abnormal urine homeostasis J:281365
decreased circulating glucose level J:281365
decreased circulating insulin level J:281365
decreased circulating ketone body level J:281365
decreased fasting circulating glucose level J:281365
decreased liver triglyceride level J:281365
decreased susceptibility to diet-induced obesity J:281365
decreased urine uric acid level J:281365
homeostasis/metabolism phenotype J:281365
impaired gluconeogenesis J:281365
improved glucose tolerance J:281365
increased circulating cholesterol level J:281365
increased circulating triglyceride level J:281365
increased insulin sensitivity J:281365
increased liver glycogen level J:281365
A4galttm1Kfk/A4galttm1Kfk
(involves: C57BL/6)
decreased physiological sensitivity to xenobiotic J:108352
decreased sensitivity to xenobiotic induced morbidity/mortality J:108352
A830019P07Riktm1a(KOMP)Wtsi/A830019P07Riktm1a(KOMP)Wtsi
(C57BL/6N-A830019P07Riktm1a(KOMP)Wtsi)
homeostasis/metabolism phenotype J:287356
Atm1Brd/Atm1Brd
Ypel4tm1a(EUCOMM)Wtsi/Ypel4tm1a(EUCOMM)Wtsi

(C57BL/6N-Atm1Brd Ypel4tm1a(EUCOMM)Wtsi/WtsiIeg)
increased circulating erythropoietin level J:313842
Aw-J/Aw-J
(C57BL/6J-Aw-J/J)
decreased circulating pituitary hormone level J:52183
Ay/a
(involves: KK)
abnormal lipid homeostasis J:26460
hyperglycemia J:26460
impaired glucose tolerance J:26460
increased circulating insulin level J:26460
increased urine glucose level J:26460
insulin resistance J:26460
Ay/a
Apoetm1Unc/Apoetm1Unc

(involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)
decreased circulating adiponectin level J:177084
hyperglycemia J:177084
increased circulating cholesterol level J:177084
increased circulating insulin level J:177084
increased circulating leptin level J:177084
increased circulating triglyceride level J:177084
insulin resistance J:177084
Ay/a
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Mae/Ccr2tm1Mae

(involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)
decreased circulating adiponectin level J:177084
homeostasis/metabolism phenotype J:177084
increased circulating cholesterol level J:177084
increased circulating leptin level J:177084
Ay/a
Rmi1Gt(pUHachi)0283Imeg/Rmi1+

(involves: C57BL/6 * KK)
decreased circulating glucose level J:168271
improved glucose tolerance J:168271
Ay/A
(involves: C57BL/6)
increased circulating leptin level J:131039
Aaastm1Ahue/Aaastm1Ahue
(involves: 129P2/OlaHsd * C57BL/6)
homeostasis/metabolism phenotype J:106908
Aak1tm1b(EUCOMM)Hmgu/Aak1tm1b(EUCOMM)Hmgu
(C57BL/6N-Aak1tm1b(EUCOMM)Hmgu/Orl)
decreased circulating cholesterol level J:211773
decreased circulating serum albumin level J:211773
decreased circulating total protein level J:211773
impaired glucose tolerance J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating aspartate transaminase level J:211773
Aarssti/Aarstm1Slac
(involves: C57BL/6J)
abnormal autophagy J:216802
Aasdhppttm1.1(KOMP)Vlcg/Aasdhppt+
(B6N(Cg)-Aasdhppttm1.1(KOMP)Vlcg/J)
improved glucose tolerance J:211773
Abca1m4620Dajl/Abca1+
(involves: C3H/HeSnJ * C57BL/6J * SWR)
decreased circulating cholesterol level J:149088
decreased circulating HDL cholesterol level J:149088
Abca1m4620Dajl/Abca1m4620Dajl
(involves: C3H/HeSnJ * C57BL/6J * SWR)
decreased circulating cholesterol level J:149088
decreased circulating HDL cholesterol level J:149088
increased circulating triglyceride level J:149088
Abca1mpc227H/Abca1mpc227H
(involves: BALB/c * C3H/HeH * C57BL/6J)
decreased circulating cholesterol level J:234901
Abca1tm1.1Jp/Abca1tm1.1Jp
(involves: 129S6/SvEvTac * C57BL/6)
abnormal circulating phospholipid level J:98093
decreased circulating cholesterol level J:98093
decreased circulating HDL cholesterol level J:98093
Abca1tm1Blt/Abca1tm1Blt
(C57BL/6-Abca1tm1Blt)
abnormal platelet physiology J:95088
Abca1tm1Jdm/Abca1+
(DBA/1LacJ-Abca1tm1Jdm)
abnormal circulating phospholipid level J:61679
abnormal lipid homeostasis J:61679
decreased circulating cholesterol level J:61679
decreased circulating HDL cholesterol level J:61679
decreased circulating LDL cholesterol level J:61679
Abca1tm1Jdm/Abca1tm1Jdm
(DBA/1LacJ-Abca1tm1Jdm)
abnormal circulating phospholipid level J:61679
abnormal fat-soluble vitamin level J:60210
abnormal lipid homeostasis J:61679
decreased circulating cholesterol level J:60210, J:61679
decreased circulating HDL cholesterol level J:60210, J:61679
decreased circulating LDL cholesterol level J:61679
increased intestinal cholesterol absorption J:61679
Abca1tm1Jdm/Abca1tm1Jdm
(involves: DBA/1LacJ)
abnormal cholesterol homeostasis J:89906
abnormal testosterone level J:89906
decreased cholesterol efflux J:89906
decreased circulating HDL cholesterol level J:89906
decreased circulating phytosterol level J:87209
Abca1tm1Jdm/Abca1tm1Jdm
(DBA/1-Abca1tm1Jdm/J)
increased cholesterol efflux J:130777
Abca1tm1Jdm/Abca1tm1Jdm
(involves: C57BL/6 * DBA/1LacJ)
decreased circulating cholesterol level J:132254
decreased circulating HDL cholesterol level J:132254
homeostasis/metabolism phenotype J:132254
Abca1tm1Jdm/Abca1tm1Jdm
Abcg1tm1Dgen/Abcg1tm1Dgen

(involves: 129P2/OlaHsd * C57BL/6 * DBA/1LacJ)
decreased cholesterol efflux J:130777
Abca1tm1Jdm/Abca1tm1Jdm
Tg(Thy1-APP)3Somm/0

(involves: C57BL/6J * DBA/1LacJ * DBA/2)
amyloidosis J:105902
cerebral amyloid angiopathy J:105902
Abca1tm1Jdm/Abca1tm1Jdm
Tgm2tm1Gml/Tgm2tm1Gml

(involves: C57BL/6 * DBA/1LacJ)
decreased circulating cholesterol level J:132254
decreased circulating HDL cholesterol level J:132254
homeostasis/metabolism phenotype J:132254
Abca1tm1Jp/Abca1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S6/SvEvTac * B6.Cg-Tg(Alb-cre)21Mgn/J)
abnormal cholesterol homeostasis J:98093
abnormal circulating phospholipid level J:98093
decreased circulating cholesterol level J:98093
decreased circulating HDL cholesterol level J:98093
Abca1tm1Jp/Abca1+
Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
decreased circulating cholesterol level J:107802
decreased circulating HDL cholesterol level J:107802
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S6/SvEvTac * B6.Cg-Tg(Alb-cre)21Mgn/J)
abnormal cholesterol homeostasis J:98093
abnormal circulating phospholipid level J:98093
decreased circulating cholesterol level J:98093
decreased circulating HDL cholesterol level J:98093
decreased circulating LDL cholesterol level J:98093
increased circulating triglyceride level J:98093
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S6/SvEvTac * C57BL/6 * DBA)
decreased circulating HDL cholesterol level J:107802
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA * SJL)
decreased circulating HDL cholesterol level J:107802
Abca1tm1Jp/Abca1tm1Jp
Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
decreased cholesterol efflux J:107802
decreased circulating cholesterol level J:107802
decreased circulating HDL cholesterol level J:107802
decreased circulating LDL cholesterol level J:107802
Abca1tm1Wpfl/Abca1+
(involves: 129P2/OlaHsd * C57BL/6J)
decreased circulating cholesterol level J:64390
decreased circulating HDL cholesterol level J:64390
Abca1tm1Wpfl/Abca1tm1Wpfl
(involves: 129P2/OlaHsd * C57BL/6J)
decreased circulating cholesterol level J:68431, J:64390
decreased circulating estradiol level J:64390
decreased circulating HDL cholesterol level J:68431, J:64390
decreased circulating progesterone level J:64390
decreased intestinal cholesterol absorption J:68431
Abca1tm1Wpfl/Abca1tm1Wpfl
Npc1m1N/Npc1m1N

(involves: 129P2/OlaHsd * BALB/c)
decreased brain cholesterol level J:130969
increased cholesterol level J:130969
Abca1tm2Jp/Abca1+
Tg(APOA1)427Bres/?

(involves: 129X1/SvJ * C57BL/6J * CBA/J)
abnormal circulating cholesterol level J:104719
abnormal circulating protein level J:104719
decreased circulating HDL cholesterol level J:104719
decreased circulating phospholipid level J:104719
Abca1tm2Jp/Abca1tm2Jp
Tg(APOA1)427Bres/?

(involves: 129X1/SvJ * C57BL/6J * CBA/J)
abnormal circulating cholesterol level J:104719
abnormal circulating protein level J:104719
decreased circulating HDL cholesterol level J:104719
decreased circulating phospholipid level J:104719
Abca2tm1Nina/Abca2tm1Nina
(involves: 129X1/SvJ * C57BL/6)
abnormal lipid level J:123521
Abca3tm1Frm/Abca3tm1Frm
(involves: 129S/SvEv)
abnormal lipid homeostasis J:120296
cyanosis J:120296
Abca3tm1Holz/Abca3tm1Holz
(involves: 129S6/SvEvTac * C57BL/6)
cyanosis J:122736
Abca3tm1Nina/Abca3tm1Nina
(involves: 129P2/OlaHsd * C57BL/6J)
cyanosis J:121155
Abca4tm1Ght/Abca4tm1Ght
(involves: 129S4/SvJae)
abnormal vitamin A level J:141801
Abca5tm1Akya/Abca5tm1Akya
(involves: C57BL/6NCrj * CBA/JNCrj)
abnormal cardiac thrombosis J:99152
Abca5tm1Akya/Abca5tm1Akya
(involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)
abnormal cardiac thrombosis J:99152
edema J:99152
Abca6em1Nju/Abca6em1Nju
(C57BL/6J-Abca6em1Nju)
homeostasis/metabolism phenotype J:311129
Abca6tm2b(KOMP)Wtsi/Abca6tm2b(KOMP)Wtsi
(C57BL/6N-Abca6tm2b(KOMP)Wtsi/Tcp)
decreased circulating serum albumin level J:211773
increased circulating aspartate transaminase level J:211773
Abca7tm1Frm/Abca7tm1Frm
(involves: 129S4/SvJae * C57BL/6)
decreased circulating cholesterol level J:96865
decreased circulating HDL cholesterol level J:96865
Abca7tm2b(EUCOMM)Hmgu/Abca7tm2b(EUCOMM)Hmgu
(B6N(Cg)-Abca7tm2b(EUCOMM)Hmgu/J)
decreased circulating chloride level J:211773
decreased circulating glucose level J:211773
decreased circulating iron level J:211773
increased fasting circulating glucose level J:211773
Abca8btm1a(EUCOMM)Wtsi/Abca8btm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased circulating cholesterol level J:269226
decreased circulating HDL cholesterol level J:269226
decreased circulating LDL cholesterol level J:269226
decreased circulating triglyceride level J:269226
Abca12el12/Abca12+
(involves: 129/Sv * C57BL/6)
abnormal lipid homeostasis J:161652
decreased cholesterol efflux J:161652
Abca12el12/Abca12el12
(involves: 129/Sv * C57BL/6)
abnormal lipid homeostasis J:161652
decreased cholesterol efflux J:161652
dehydration J:161652
impaired skin barrier function J:161652
increased cholesterol level J:161652
Abca12em1(IMPC)J/Abca12em1(IMPC)J
(C57BL/6NJ-Abca12em1(IMPC)J/Mmjax)
edema J:211773
Abca12smsk/Abca12smsk
(involves: C57BL/6J)
dehydration J:262458
impaired skin barrier function J:262458
Abca12tm1Lex/Abca12tm1Lex
(involves: 129S/SvEvBrd * C57BL/6J)
abnormal lipid homeostasis J:144062
impaired skin barrier function J:144062
Abca12tm1Shzu/Abca12tm1Shzu
(B6.129S-Abca12tm1Shzu)
dehydration J:139048
impaired skin barrier function J:139048
Abca13tm1b(EUCOMM)Wtsi/Abca13tm1b(EUCOMM)Wtsi
(C57BL/6N-Abca13tm1b(EUCOMM)Wtsi/Bay)
decreased circulating alkaline phosphatase level J:211773
Abca17tm1b(EUCOMM)Wtsi/Abca17tm1b(EUCOMM)Wtsi
(C57BL/6N-Abca17tm1b(EUCOMM)Wtsi/Bay)
decreased circulating potassium level J:211773
increased circulating alkaline phosphatase level J:211773
Abcb1amds/Abcb1amds
(involves: CF-1)
increased physiological sensitivity to xenobiotic J:40292, J:64725
Abcb1atm1Bor/Abcb1atm1Bor
(involves: 129P2/OlaHsd * FVB)
abnormal xenobiotic pharmacokinetics J:39804
increased physiological sensitivity to xenobiotic J:18554
Abcb1atm1Bor/Abcb1atm1Bor
(FVBTac.129P2-Abcb1atm1Bor)
abnormal xenobiotic pharmacokinetics J:59145, J:102640
increased physiological sensitivity to xenobiotic J:59145
increased susceptibility to ototoxicity-induced hearing loss J:59145
Abcb1atm1Bor/Abcb1atm1Bor
Abcb1btm1Bor/Abcb1btm1Bor

(involves: 129P2/OlaHsd * FVB)
abnormal xenobiotic pharmacokinetics J:39804
Abcb1atm1Bor/Abcb1atm1Bor
Abcb1btm1Bor/Abcb1btm1Bor

(FVBTac.129P2-Abcb1btm1Bor Abcb1atm1Bor)
abnormal xenobiotic pharmacokinetics J:102640, J:107822
Abcb1atm1Bor/Abcb1atm1Bor
Abcb1btm1Bor/Abcb1btm1Bor
Abcc2tm1Ahs/Abcc2tm1Ahs

(FVB.129P2-Abcb1btm1Bor Abcb1atm1Bor Abcc2tm1Ahs)
abnormal xenobiotic pharmacokinetics J:107822
Abcb1atm1Bor/Abcb1atm1Bor
Abcb1btm1Bor/Abcb1btm1Bor
Tg(Thy1-AppDutch)#Jckr/0

(FVB.Cg-Abcb1btm1Bor Abcb1atm1Bor Tg(Thy1-AppDutch)#Jckr)
amyloid beta deposits J:178230
Abcb1atm1Bor/Abcb1atm1Bor
Abcb1btm1Bor/Abcb1btm1Bor
Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr/0

(FVB.Cg-Abcb1btm1Bor Abcb1atm1Bor Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr)
amyloid beta deposits J:178230
Abcb1atm1Bor/Abcb1atm1Bor
Npc1m1N/Npc1m1N

(involves: 129/Ola * BALB/c)
increased liver cholesterol level J:76395
Abcb1btm2Bor/Abcb1btm2Bor
(involves: 129P2/OlaHsd * FVB)
abnormal xenobiotic pharmacokinetics J:39804
Abcb4em1(IMPC)H/Abcb4em1(IMPC)H
(C57BL/6NTac-Abcb4em1(IMPC)H/H)
decreased circulating glucose level J:211773
decreased circulating HDL cholesterol level J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating bilirubin level J:211773
increased circulating creatinine level J:211773
increased circulating potassium level J:211773
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
abnormal blood homeostasis J:15531
abnormal circulating alanine transaminase level J:15531
abnormal circulating alkaline phosphatase level J:15531
abnormal circulating aspartate transaminase level J:15531
abnormal circulating bilirubin level J:15531
Abcb4tm1Bor/Abcb4tm1Bor
(involves: 129P2/OlaHsd * FVB/N)
abnormal circulating enzyme level J:114411
abnormal lipid homeostasis J:114411
abnormal sodium ion homeostasis J:175015
decreased circulating cholesterol level J:114411
decreased intestinal cholesterol absorption J:114411
increased bile salt level J:175015
increased circulating alanine transaminase level J:114411, J:175015
increased circulating aspartate transaminase level J:114411
increased circulating bilirubin level J:114411
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
abnormal circulating enzyme level J:105357
homeostasis/metabolism phenotype J:100491
increased circulating alanine transaminase level J:100491, J:217802
increased circulating alkaline phosphatase level J:105357, J:217802
increased circulating aspartate transaminase level J:100491, J:217802
increased circulating bilirubin level J:105357, J:217802
Abcb4tm1Bor/Abcb4tm1Bor
(C.129P2-Abcb4tm1Bor)
abnormal enzyme/coenzyme activity J:199949
decreased circulating calcium level J:199949
decreased vitamin D level J:199949
increased alkaline phosphatase activity J:199949
increased circulating phosphate level J:199949
increased transforming growth factor beta level J:199949
increased tumor necrosis factor (ligand) superfamily member 11 level J:199949
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
increased circulating alanine transaminase level J:217802
increased circulating alkaline phosphatase level J:217802
increased circulating aspartate transaminase level J:217802
increased circulating bilirubin level J:217802
Abcb4tm1Bor/Abcb4tm1Bor
Pemttm1J/Pemttm1J

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
decreased bile salt level J:175015
decreased circulating alanine transaminase level J:175015
Abcb4tm1Bor/Abcb4tm1Bor
Portm1Wolf/Portm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129P2/OlaHsd * C57BL/6 * DBA * FVB/N)
abnormal bile salt homeostasis J:215915
increased bile salt level J:215915
increased circulating alanine transaminase level J:215915
increased circulating alkaline phosphatase level J:215915
increased circulating bilirubin level J:215915
Abcb4tm1Bor/Abcb4tm1Bor
Tg(ABCG5/ABCG8)14-2Hobb/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
decreased intestinal cholesterol absorption J:100491
homeostasis/metabolism phenotype J:100491
increased circulating alanine transaminase level J:100491
increased circulating aspartate transaminase level J:100491
Abcb5tm1.2Nyf/Abcb5tm1.2Nyf
(involves: 129S6/SvEvTac * C57BL/6)
abnormal corneal wound healing J:213708
Abcb6tm1Jsch/Abcb6tm1Jsch
(involves: 129)
increased physiological sensitivity to xenobiotic J:184574
increased sensitivity to xenobiotic induced morbidity/mortality J:184574
Abcb6tm1Pkr/Abcb6tm1Pkr
(involves: C57BL/6)
decreased physiological sensitivity to xenobiotic J:190243
Abcb7tm1Mdf/Y
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(either: B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Abcb7tm1Mdf or (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA))
abnormal circulating enzyme level J:106838
abnormal enzyme/coenzyme activity J:106838
hemosiderosis J:106838
Abcb8tm1Hard/Abcb8tm1Hard
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+

(involves: FVB)
increased heart iron level J:182234
Abcb10tm1.1Tafu/Abcb10tm1.2Tafu
Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * C57BL/6NCrlj * CBA/J * CBA/JNCrlJ)
abnormal iron level J:223428
Abcb10tm1.2Tafu/Abcb10tm1.2Tafu
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal iron level J:223428
Abcb10tm1Lex/Abcb10+
(involves: 129S/SvEvBrd * C57BL/6)
increased response of heart to induced stress J:189396
Abcb11tm1a(EUCOMM)Hmgu/Abcb11tm1a(EUCOMM)Hmgu
(C57BL/6N-Abcb11tm1a(EUCOMM)Hmgu/Ieg)
increased circulating alanine transaminase level J:165965
increased circulating alkaline phosphatase level J:165965
increased circulating aspartate transaminase level J:165965
increased circulating potassium level J:165965
Abcb11tm1b(EUCOMM)Hmgu/Abcb11+
(C57BL/6N-Abcb11tm1b(EUCOMM)Hmgu/Ieg)
decreased circulating triglyceride level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating amylase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating bilirubin level J:211773
increased circulating fructosamine level J:211773
increased circulating unsaturated transferrin level J:211773
Abcb11tm1Wng/Abcb11tm1Wng
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal bile salt level J:67548
abnormal phospholipid level J:67548
decreased liver glycogen level J:67548
increased bile salt level J:67548
increased cholesterol level J:67548
Abcc1tm1Acs/Abcc1tm1Acs
(involves: 129S1/Sv * C57BL/6)
abnormal homeostasis J:44305
increased physiological sensitivity to xenobiotic J:44305
Abcc1tm1Bor/Abcc1tm1Bor
(involves: 129P2/OlaHsd * FVB)
increased physiological sensitivity to xenobiotic J:44110
increased sensitivity to xenobiotic induced morbidity/mortality J:44110
Abcc1tm1Bor/Abcc1tm1Bor
Tg(Thy1-AppDutch)#Jckr/0

(FVB.Cg-Abcc1tm1Bor Tg(Thy1-AppDutch)#Jckr)
abnormal homeostasis J:178230
amyloid beta deposits J:178230
Abcc1tm1Bor/Abcc1tm1Bor
Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr/0

(FVB.Cg-Abcc1tm1Bor Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr)
amyloid beta deposits J:178230
Abcc2tm1.1(ABCC2)Arte/Abcc2tm1.1(ABCC2)Arte
(C57BL/6-Abcc2tm1.1(ABCC2)Arte)
homeostasis/metabolism phenotype J:208127
Abcc2tm1.1(ABCC2)Arte/Abcc2tm1.1(ABCC2)Arte
Nr1i2tm1(NR1I2)Arte/Nr1i2tm1(NR1I2)Arte

(involves: C57BL/6)
homeostasis/metabolism phenotype J:216646
Abcc2tm1Ahs/Abcc2tm1Ahs
(involves: 129P2/OlaHsd * FVB)
abnormal blood homeostasis J:107822
abnormal xenobiotic pharmacokinetics J:107822
bilirubinuria J:107822
increased circulating bilirubin level J:107822
Abcc2tm1Ahs/Abcc2tm1Ahs
(FVB.129P2-Abcc2tm1Ahs)
abnormal xenobiotic pharmacokinetics J:107822
bilirubinuria J:216646
increased circulating bilirubin level J:216646
Abcc2tm1Ahs/Abcc2tm1Ahs
(B6.129P2(FVB)-Abcc2tm1Ahs)
increased circulating bilirubin level J:208127
increased physiological sensitivity to xenobiotic J:208127
Abcc2tm1Dgen/Abcc2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating alkaline phosphatase level J:134950
increased circulating bilirubin level J:134950
increased circulating cholesterol level J:134950
Abcc2tm2b(KOMP)Wtsi/Abcc2tm2b(KOMP)Wtsi
(C57BL/6N-Abcc2tm2b(KOMP)Wtsi/H)
increased circulating alanine transaminase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating bilirubin level J:211773
increased circulating cholesterol level J:211773
increased circulating HDL cholesterol level J:211773
Abcc3tm1Bor/Abcc3tm1Bor
(involves: 129P2/Ola * FVB/N)
abnormal bile salt homeostasis J:149653
abnormal xenobiotic pharmacokinetics J:99234
Abcc3tm1Bor/Abcc3tm1Bor
(FVB.129P2-Abcc3tm1Bor)
abnormal xenobiotic pharmacokinetics J:99234
Abcc3tm1Kruh/Abcc3tm1Kruh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal bile salt level J:114229
increased circulating bilirubin level J:114229
Abcc3tm1Kruh/Abcc3tm1Kruh
Slc51atm1Pda/Slc51atm1Pda

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
abnormal bile salt homeostasis J:132778
Abcc4Gt(RRC212)Byg/Abcc4Gt(RRC212)Byg
(involves: 129P2/OlaHsd * C57BL/6)
decreased prostaglandin level J:139829
Abcc4tm1Jsch/Abcc4tm1Jsch
(involves: 129X1/SvJ)
abnormal urine organic anion level J:92788
Abcc4tm1Kruh/Abcc4tm1Kruh
(B6.129-Abcc4tm1Kruh)
abnormal blood homeostasis J:117326
Abcc5em1(IMPC)H/Abcc5em1(IMPC)H
(C57BL/6N-Abcc5em1(IMPC)H/H)
decreased circulating calcium level J:211773
decreased circulating glucose level J:211773
impaired glucose tolerance J:211773
increased blood urea nitrogen level J:211773
Abcc6tm1Aabb/Abcc6tm1Aabb
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating HDL cholesterol level J:105062
increased circulating creatinine level J:105062
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
E2f1Tg(Wnt1-cre)2Sor/?

(B6.Cg-E2f1Tg(Wnt1-cre)2Sor Abcc6tm1c(EUCOMM)Wtsi)
calcinosis J:252837
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
E2f1Tg(Wnt1-cre)2Sor/?
Speer6-ps1Tg(Alb-cre)21Mgn/?

(B6.Cg-E2f1Tg(Wnt1-cre)2Sor Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn)
calcinosis J:252837
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/?

(B6.Cg-Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn)
calcinosis J:252837
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/?
Tg(Cdx1-cre)23Kem/?

(B6.Cg-Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn Tg(Cdx1-cre)23Kem)
calcinosis J:252837
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
Tg(CMV-cre)1Cgn/?

(B6.Cg-Abcc6tm1c(EUCOMM)Wtsi Tg(CMV-cre)1Cgn)
calcinosis J:252837
Abcc6tm1Jfk/Abcc6tm1Jfk
(involves: 129S1/Sv * C57BL/6J)
calcinosis J:101372
Abcc6tm1Jfk/Abcc6tm1Jfk
(B6.129S1-Abcc6tm1Jfk)
calcinosis J:252837
Abcc6tm1Jfk/Abcc6tm1Jfk
Enpp1asj/Enpp1+

(B6.Cg-Abcc6tm1Jfk Enpp1asj)
calcinosis J:252837
Abcc6tm1Jfk/Abcc6tm1Jfk
Enpp1asj/Enpp1asj

(B6.Cg-Abcc6tm1Jfk Enpp1asj)
calcinosis J:252837
Abcc6tm1Jfk/Abcc6tm1Jfk
Nt5etm1Lft/Nt5etm1Lft

(B6.Cg-Abcc6tm1Jfk Nt5etm1Lft)
calcinosis J:252837
Abcc6tm1Jfk/Abcc6tm1Jfk
Samd9ltm1Homy/Samd9ltm1Homy

(B6.129-Samd9ltm1Homy Abcc6tm1Jfk)
calcinosis J:225110
Abcc8em1(IMPC)J/Abcc8em1(IMPC)J
(C57BL/6NJ-Abcc8em1(IMPC)J/Mmjax)
impaired glucose tolerance J:211773
Abcc8tm1.1Fmas/Abcc8tm1.1Fmas
(B6.129S2(Cg)-Abcc8tm1.1Fmas)
decreased circulating glucose level J:208932
decreased insulin secretion J:208932
homeostasis/metabolism phenotype J:208932
impaired glucose tolerance J:208932
increased circulating glucose level J:208932
increased insulin secretion J:208932
Abcc8tm1.1Mgn/Abcc8tm1.1Mgn
(involves: 129X1/SvJ * C57BL/6)
decreased insulin secretion J:79352
hypoglycemia J:79352
impaired glucose tolerance J:79352
Abcc8tm1Jbry/Abcc8tm1Jbry
(involves: 129X1/SvJ * C57BL/6)
hypoglycemia J:61356
impaired glucose tolerance J:61356
Abcc8tm1Jbry/Abcc8tm1Jbry
(involves: 129X1/SvJ)
abnormal insulin secretion J:179577
decreased circulating glucose level J:179577
decreased insulin secretion J:179577
increased circulating glucose level J:179577
Abcc8tm1Jbry/Abcc8tm1Jbry
Sstr5tm1Fcb/Sstr5tm1Fcb

(involves: 129X1/SvJ)
abnormal insulin secretion J:179577
decreased circulating glucose level J:179577
decreased insulin secretion J:179577
increased circulating glucose level J:179577
Abcc9em3Nich/Abcc9em3Nich
(B6.Cg-Abcc9em3Nich)
abnormal physiological response to xenobiotic J:308986
Abcc9tm1.1Mcn/Abcc9tm1.1Mcn
Tg(Tagln-cre)1Her/0

(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased fatty acid oxidation J:216539
decreased oxygen consumption J:216539
homeostasis/metabolism phenotype J:216539
hypoxia J:216539
Abcc9tm1Cfb/Abcc9tm1Cfb
(involves: CD-1)
hypoglycemia J:71840
improved glucose tolerance J:71840
increased insulin sensitivity J:71840
Abcc10tm1Eah/Abcc10tm1Eah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased physiological sensitivity to xenobiotic J:172648
Abcd1tm1Kan/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal lipid homeostasis J:44812
Abcd1tm1Kan/Y
(involves: 129 * BALB/cJ * C57BL/6J * Swiss)
increased fatty acids level J:257393
Abcd1tm1Kan/Y
Gt(ROSA)26Sortm2.1(CAG-ELOVL1)Geno/Gt(ROSA)26Sor+
Cnptm1(cre)Kan/Cnp+

(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased fatty acids level J:257393
Abcd1tm1Kan/Y
Gt(ROSA)26Sortm2.1(CAG-ELOVL1)Geno/Gt(ROSA)26Sor+
Tg(CMV-cre)1Cgn/0

(involves: 129 * BALB/cJ * C57BL/6J * Swiss)
increased fatty acids level J:257393
Abcd1tm1Kan/Abcd1tm1Kan
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal lipid homeostasis J:44812
Abcd1tm1Kds/Y
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
abnormal lipid homeostasis J:42479
increased saturated fatty acids level J:42479
Abcd1tm1Kds/Y
(involves: 129S4/SvJae * C57BL/6J)
increased fatty acids level J:94583
Abcd1tm1Kds/Y
Abcd2tm1Apuj/Abcd2tm1Apuj

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
increased fatty acids level J:94583, J:104122
Abcd1tm1Kds/Abcd1tm1Kds
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
abnormal lipid homeostasis J:42479
increased saturated fatty acids level J:42479
Abcd1tm1Ymd/Y
(involves: 129S/SvEv * C57BL/6J * DBA/2J)
abnormal lipid homeostasis J:40230
Abcd1tm1Ymd/Abcd1tm1Ymd
(involves: 129S/SvEv * C57BL/6J * DBA/2J)
abnormal lipid homeostasis J:40230
Abcd2tm1Apuj/Abcd2tm1Apuj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased fatty acids level J:94583, J:104122
Abcd3em1(IMPC)J/Abcd3em1(IMPC)J
(C57BL/6NJ-Abcd3em1(IMPC)J/J)
improved glucose tolerance J:211773
increased circulating calcium level J:211773
increased fasting circulating glucose level J:211773
Abcd3tm1Safe/Abcd3tm1Safe
(involves: 129S4/SvJae * C57BL/6J)
abnormal blood homeostasis J:217065
Abce1tm1b(EUCOMM)Hmgu/Abce1+
(C57BL/6N-Abce1tm1b(EUCOMM)Hmgu/H)
decreased circulating creatinine level J:211773
Abcg1tm1Asch/Abcg1tm1Asch
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to diet-induced obesity J:122438
hypoglycemia J:122438
increased body temperature J:122438
increased energy expenditure J:122438
increased oxygen consumption J:122438
Abcg1tm1Dgen/Abcg1+
Abcg4tm1Dgen/Abcg4tm1Dgen

(involves: 129P2/OlaHsd)
abnormal lipid homeostasis J:141549
abnormal lipid level J:141549
decreased cholesterol efflux J:141549
Abcg1tm1Dgen/Abcg1tm1Dgen
(B6.129P2-Abcg1tm1Dgen)
abnormal phospholipid level J:117028
increased cholesterol level J:117028
increased triglyceride level J:117028
Abcg1tm1Dgen/Abcg1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
decreased cholesterol efflux J:130777
lipidosis J:132952
Abcg1tm1Dgen/Abcg1tm1Dgen
(involves: 129P2/OlaHsd)
abnormal lipid level J:141549
Abcg1tm1Dgen/Abcg1tm1Dgen
Abcg4tm1Dgen/Abcg4+

(involves: 129P2/OlaHsd)
abnormal lipid homeostasis J:141549
abnormal lipid level J:141549
decreased cholesterol efflux J:141549
Abcg1tm1Dgen/Abcg1tm1Dgen
Abcg4tm1Dgen/Abcg4tm1Dgen

(involves: 129P2/OlaHsd)
abnormal cholesterol homeostasis J:141549
abnormal lipid homeostasis J:141549
abnormal lipid level J:141549
decreased cholesterol efflux J:141549
Abcg2em1Omw/Abcg2em1Omw
(C57BL/6J-Abcg2em1Omw)
increased blood uric acid level J:292268
increased circulating glucose level J:292268
increased circulating insulin level J:292268
increased circulating insulin-like growth factor I level J:292268
increased circulating potassium level J:292268
increased urine osmolality J:292268
increased urine sodium level J:292268
Abcg2tm1.1(KOMP)Vlcg/Abcg2tm1.1(KOMP)Vlcg
(B6N(Cg)-Abcg2tm1.1(KOMP)Vlcg/J)
decreased blood urea nitrogen level J:211773
increased circulating cholesterol level J:211773
increased circulating HDL cholesterol level J:211773
Abcg2tm1.1Ssf/Abcg2tm1.1Ssf
(involves: 129 * C57BL/6 * FVB)
abnormal glucose homeostasis J:201884
decreased liver glycogen level J:201884
impaired glucose tolerance J:201884
increased porphyrin level J:201884
Abcg2tm1Ahs/Abcg2tm1Ahs
(either: (involves: 129P2/OlaHsd * FVB) or (involves: FVB))
homeostasis/metabolism phenotype J:80519
increased circulating bilirubin level J:80519
phototoxicity J:80519
porphyria J:80519
Abcg2tm1Ahs/Abcg2tm1Ahs
(FVB.129P2-Abcg2tm1Ahs/Tac)
abnormal homeostasis J:220924
increased blood uric acid level J:220924
increased urine uric acid level J:220924
Abcg2tm1Ahs/Abcg2tm1Ahs
Tg(Thy1-AppDutch)#Jckr/0

(FVB.Cg-Abcg2tm1Ahs Tg(Thy1-AppDutch)#Jckr)
amyloid beta deposits J:178230
Abcg2tm1Ahs/Abcg2tm1Ahs
Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr/0

(FVB.Cg-Abcg2tm1Ahs Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr)
amyloid beta deposits J:178230
Abcg2tm1Bsor/Abcg2tm1Bsor
(involves: 129P2/OlaHsd * C57BL/6)
increased physiological sensitivity to xenobiotic J:98134
Abcg4tm1Dgen/Abcg4tm1Dgen
(Not Specified)
abnormal lipid level J:141549
Abcg5tm1.1Hobb/Abcg5tm1.1Hobb
Abcg8tm1.1Hobb/Abcg8tm1.1Hobb
Speer6-ps1Tg(Alb-cre)21Mgn/?

(involves: C57BL/6 * DBA * SJL)
abnormal cellular cholesterol metabolism J:215443
abnormal intestinal cholesterol absorption J:215443
abnormal phytosterol level J:215443
decreased cholesterol efflux J:215443
decreased circulating cholesterol level J:215443
decreased phytosterol level J:215443
increased cholesterol level J:215443
increased circulating phytosterol level J:215443
Abcg5tm1.1Hobb/Abcg5tm1.1Hobb
Abcg8tm1.1Hobb/Abcg8tm1.1Hobb
Tg(CAG-cre/Esr1*)5Amc/?

(involves: C57BL/6 * CBA * SJL)
abnormal cellular cholesterol metabolism J:215443
abnormal phytosterol level J:215443
decreased cholesterol efflux J:215443
decreased cholesterol level J:215443
decreased circulating cholesterol level J:215443
decreased phytosterol level J:215443
increased circulating phytosterol level J:215443
increased intestinal phytosterol absorption J:215443
increased phytosterol level J:215443
Abcg5tm1.1Hobb/Abcg5tm1.1Hobb
Abcg8tm1.1Hobb/Abcg8tm1.1Hobb
Tg(Vil1-cre)997Gum/?

(involves: C57BL/6 * SJL)
abnormal cellular cholesterol metabolism J:215443
decreased cholesterol efflux J:215443
increased circulating phytosterol level J:215443
increased intestinal phytosterol absorption J:215443
increased phytosterol level J:215443
Abcg5tm1Plo/Abcg5tm1Plo
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal metabolism J:87209
abnormal phospholipid level J:87209
decreased cholesterol level J:87209
decreased circulating cholesterol level J:87209
increased circulating phytosterol level J:87209
increased circulating triglyceride level J:87209
increased circulating VLDL triglyceride level J:87209
Abcg5tm1Plo/Abcg5tm1Plo
(involves: 129P2/OlaHsd)
abnormal cholesterol homeostasis J:112995
abnormal lipid homeostasis J:112995
Abcg5trac/Abcg5trac
(A/J-Abcg5trac)
abnormal circulating cholesterol level J:157223
abnormal circulating lipid level J:157223
abnormal platelet activation J:157223
decreased platelet aggregation J:157223
increased bleeding time J:157223
Abcg8tm1b(KOMP)Wtsi/Abcg8tm1b(KOMP)Wtsi
(C57BL/6N-Abcg8tm1b(KOMP)Wtsi/Ccpcz)
abnormal cholesterol homeostasis J:211773
decreased circulating iron level J:211773
decreased circulating serum albumin level J:211773
decreased circulating sodium level J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating cholesterol level J:211773
increased circulating creatinine level J:211773
increased circulating potassium level J:211773
increased circulating triglyceride level J:211773
increased fasting circulating glucose level J:211773
Abcg8tm1Elk/Abcg8+
(involves: 129S6/SvEvTac * C57BL/6J)
decreased circulating cholesterol level J:94759
Abcg8tm1Elk/Abcg8tm1Elk
(involves: 129S6/SvEvTac * C57BL/6J)
decreased cholesterol level J:94759
decreased circulating cholesterol level J:94759
increased circulating phytosterol level J:94759
increased circulating triglyceride level J:94759
Abhd2Gt(pUHachi)8025Imeg/Abhd2Gt(pUHachi)8025Imeg
(involves: C57BL/6NCrj * CBA/JNCrj)
abnormal vascular wound healing J:96209
Abhd4tm1Crv/Abhd4tm1Crv
(B6.129S6-Abhd4tm1Crv)
abnormal enzyme/coenzyme activity J:276423
abnormal lipid homeostasis J:276423
Abhd5tm1.1Lqyu/Abhd5tm1.1Lqyu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA)
abnormal lipid level J:199570
abnormal phospholipid level J:199570
decreased fatty acid oxidation J:199570
decreased triglyceride lipase activity J:199570
homeostasis/metabolism phenotype J:199570
increased circulating alanine transaminase level J:199570
increased circulating aspartate transaminase level J:199570
increased liver cholesterol level J:199570
increased liver free fatty acids level J:199570
increased liver triglyceride level J:199570
Abhd5tm1.1Rze/Abhd5tm1.1Rze
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lipid homeostasis J:160725
abnormal lipid level J:160725
decreased circulating glucose level J:160725
decreased circulating triglyceride level J:160725
decreased fatty acids level J:160725
decreased triglyceride lipase activity J:160725
impaired lipolysis J:160725
impaired skin barrier function J:160725
increased liver triglyceride level J:160725
increased triglyceride level J:160725
Abhd5tm1Murm/Abhd5tm1Murm
(B6.129S-Abhd5tm1Murm)
abnormal ceramide level J:240682
increased triglyceride level J:240682
Abhd5tm1Rze/Abhd5tm1Rze
Tg(Ckmm-cre)5Khn/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB)
abnormal glucose homeostasis J:197835
abnormal lipid homeostasis J:197835
decreased circulating free fatty acids level J:197835
decreased circulating glucose level J:197835
decreased circulating insulin level J:197835
decreased circulating triglyceride level J:197835
decreased lipoprotein lipase activity J:197835
decreased liver triglyceride level J:197835
decreased oxygen consumption J:197835
homeostasis/metabolism phenotype J:197835
impaired lipolysis J:197835
improved glucose tolerance J:197835
increased cardiac muscle triglyceride level J:197835
increased respiratory quotient J:197835
increased skeletal muscle triglyceride level J:197835
Abhd6tm1a(EUCOMM)Hmgu/Abhd6+
(C57BL/6N-Abhd6tm1a(EUCOMM)Hmgu)
increased insulin secretion J:215257
Abhd6tm1a(EUCOMM)Hmgu/Abhd6tm1a(EUCOMM)Hmgu
(C57BL/6N-Abhd6tm1a(EUCOMM)Hmgu)
abnormal body temperature homeostasis J:234876
abnormal enzyme/coenzyme activity J:234876
abnormal lipid level J:215257
decreased circulating insulin level J:234876
decreased insulin secretion J:234876
decreased liver triglyceride level J:234876
decreased susceptibility to diet-induced obesity J:234876
improved glucose tolerance J:234876
increased circulating insulin level J:215257
increased energy expenditure J:234876
increased fatty acid beta-oxidation J:234876
increased insulin secretion J:215257, J:234876
increased insulin sensitivity J:234876
increased oxygen consumption J:234876
Abhd6tm1c(EUCOMM)Hmgu/Abhd6tm1c(EUCOMM)Hmgu
Tg(Ins1-cre/ERT)1Lphi/0

(involves: C57BL/6N * CD-1)
improved glucose tolerance J:215257
increased circulating insulin level J:215257
increased insulin secretion J:215257
Abhd8tm1b(EUCOMM)Wtsi/Abhd8tm1b(EUCOMM)Wtsi
(C57BL/6N-Abhd8tm1b(EUCOMM)Wtsi/Bay)
decreased circulating calcium level J:211773
decreased circulating chloride level J:211773
decreased circulating cholesterol level J:211773
increased circulating potassium level J:211773
Abhd11tm1Esco/Abhd11tm1Esco
(involves: C57BL/6)
decreased circulating glucose level J:294591
decreased circulating insulin level J:294591
decreased susceptibility to diet-induced obesity J:294591
improved glucose tolerance J:294591
increased insulin sensitivity J:294591
Abhd12tm1Crv/Abhd12tm1Crv
(involves: C57BL/6)
abnormal phospholipid level J:193716
decreased lipoprotein lipase activity J:193716
Abhd12bem1(IMPC)J/Abhd12bem1(IMPC)J
(C57BL/6NJ-Abhd12bem1(IMPC)J/Mmjax)
increased fasting circulating glucose level J:211773
Abhd14atm2a(EUCOMM)Wtsi/Abhd14atm2a(EUCOMM)Wtsi
(C57BL/6N-Abhd14atm2a(EUCOMM)Wtsi/Wtsi)
decreased circulating HDL cholesterol level J:211773
improved glucose tolerance J:211773
Abhd16atm1a(EUCOMM)Wtsi/Abhd16atm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
abnormal enzyme/coenzyme activity J:232688
abnormal phospholipid level J:232688
Abhd16atm1a(EUCOMM)Wtsi/Abhd16atm1a(EUCOMM)Wtsi
(C57BL/6N-Abhd16atm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating magnesium level J:211773
decreased fasting circulating glucose level J:211773
Abhd17atm1a(KOMP)Wtsi/Abhd17atm1a(KOMP)Wtsi
(C57BL/6N-Abhd17atm1a(KOMP)Wtsi/Wtsi)
improved glucose tolerance J:211773
Abi1tm1.2Lko/Abi1tm1.2Lko
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * CBA)
cardiac edema J:171342
pericardial edema J:171342
Abi1tm1Pen/Abi1tm1Pen
(involves: CD-1)
edema J:169009
Abi2tm1b(EUCOMM)Wtsi/Abi2tm1b(EUCOMM)Wtsi
(C57BL/6N-Abi2tm1b(EUCOMM)Wtsi/Tcp)
increased circulating alanine transaminase level J:211773
increased circulating creatinine level J:211773
Abi3bptm1Tac/Abi3bptm1Tac
(involves: 129S5/SvEvBrd)
increased susceptibility to myocardial ischemic injury J:251000
Abl1tm1.1Gcos/Abl1+
(involves: 129S1/Sv * 129X1/SvJ)
decreased physiological sensitivity to xenobiotic J:168843
Abl1tm1.1Gcos/Abl1tm1.1Gcos
(involves: 129S1/Sv * 129X1/SvJ)
decreased physiological sensitivity to xenobiotic J:168843
Abl1tm1Gcos/Abl1+
Myf5tm2Tajb/Myf5tm2Tajb
Myf6tm1Tajb/Myf6tm1Tajb
Myod1tm2.1(icre)Glh/Myod1+

(involves: 129S * 129X1/SvJ * C57BL/6J)
decreased physiological sensitivity to xenobiotic J:168843
Abl1tm1Mlg/Abl1tm1Mlg
Abl2tm1Ajk/Abl2+

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J)
edema J:51887
hemopericardium J:51887
pericardial edema J:51887
Abl1tm1Mlg/Abl1tm1Mlg
Abl2tm1Ajk/Abl2tm1Ajk

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J)
hemopericardium J:51887
AblpBALB/cJ/?
(involves: BALB/cJ * C57BL/6J)
abnormal enzyme/coenzyme level J:94275
Abratm1Eno/Abratm1Eno
(Not Specified)
increased susceptibility to injury J:167793
Abraxas1tm1.1Bwng/Abraxas1tm1.1Bwng
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
abnormal double-strand DNA break repair J:269823
increased mortality induced by gamma-irradiation J:269823
Abtb1em1(IMPC)Ccpcz/Abtb1em1(IMPC)Ccpcz
(C57BL/6N-Abtb1em1(IMPC)Ccpcz/Ccpcz)
increased fasting circulating glucose level J:211773
Acacatm1Dejs/Acacatm1Dejs
Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
abnormal lipid metabolism J:209886
Acacatm1Jkus/Acacatm1Jkus
Tg(Fabp1-cre)1Mmt/0

(involves: 129X1/SvJ * C57BL/6J * SJL)
abnormal lipid homeostasis J:118861
decreased liver triglyceride level J:118861
increased circulating aspartate transaminase level J:118861
Acacatm2Sjw/Acacatm2Sjw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
abnormal enzyme/coenzyme activity J:110200
abnormal glucose homeostasis J:110200
abnormal lipid level J:110200
decreased circulating free fatty acids level J:110200
decreased circulating ketone body level J:110200
decreased fatty acids level J:110200
decreased liver triglyceride level J:110200
hyperglycemia J:110200
increased circulating free fatty acids level J:110200
increased circulating insulin level J:110200
Acacbtm1.1Dejs/Acacbtm1.1Dejs
(B6.Cg-Acacbtm1.1Dejs)
abnormal glucose homeostasis J:157000
abnormal lipid homeostasis J:157000
homeostasis/metabolism phenotype J:157000
increased fatty acid oxidation J:157000
increased skeletal muscle glycogen level J:157000
Acacbtm1.2Lowl/Acacbtm1.2Lowl
(involves: 129S6/SvEvTac * FVB/N)
abnormal enzyme/coenzyme level J:159285
decreased respiratory quotient J:159285
homeostasis/metabolism phenotype J:159285
increased circulating insulin level J:159285
increased oxygen consumption J:159285
Acacbtm1Sjw/Acacbtm1Sjw
(Not Specified)
abnormal energy expenditure J:68427
abnormal enzyme/coenzyme level J:68427
abnormal lipid homeostasis J:68427
decreased circulating free fatty acids level J:68427
decreased circulating glucose level J:68427
decreased circulating leptin level J:68427
decreased fatty acids level J:68427
decreased liver glycogen level J:68427
decreased liver triglyceride level J:68427
increased circulating ketone body level J:68427
increased circulating triglyceride level J:68427
increased fatty acid beta-oxidation J:68427
increased fatty acid oxidation J:68427
Acad8m1Ytc/Acad8m1Ytc
(involves: C57BL/6)
abnormal circulating amino acid level J:222356
abnormal circulating enzyme level J:222356
abnormal urine homeostasis J:222356
decreased circulating carnitine level J:222356
homeostasis/metabolism phenotype J:222356
impaired adaptive thermogenesis J:222356
increased oxygen consumption J:222356
Acad12tm1b(EUCOMM)Wtsi/Acad12tm1b(EUCOMM)Wtsi
(C57BL/6N-Acad12tm1b(EUCOMM)Wtsi/Wtsi)
increased circulating insulin level J:211773
Acadltm1Uab/Acadltm1Uab
(involves: 129S6/SvEvTac * C57BL/6NTac)
abnormal adaptive thermogenesis J:50729
abnormal enzyme/coenzyme activity J:72193, J:51660
abnormal lipid homeostasis J:72193
dicarboxylic aciduria J:72193, J:51660
hypoglycemia J:51660
increased circulating carnitine level J:72193
increased circulating free fatty acids level J:51660
increased fatty acids level J:72193
increased unsaturated fatty acids level J:51660
lipidosis J:51660
Acadmtm1Uab/Acadmtm1Uab
(involves: 129P2/OlaHsd * C57BL/6)
abnormal blood homeostasis J:115759
decreased circulating glucose level J:115759
impaired adaptive thermogenesis J:115759
increased circulating carnitine level J:115759
Acadsdel-J/Acads+
Otcspf/Y

(involves: BALB/cByJ * CD-1)
aciduria J:4165
oroticaciduria J:4165
Acadsdel-J/Acadsdel-J
(involves: BALB/cByJ)
abnormal adaptive thermogenesis J:50729
abnormal fatty acid oxidation J:14707
decreased circulating carnitine level J:14707
decreased circulating glycine level J:14707
ethylmalonic aciduria J:4165, J:9743
hypoglycemia J:14707
increased circulating HDL cholesterol level J:164460
organic aciduria J:14707, J:4165, J:9743
Acadsdel-J/Acadsdel-J
Otcspf/Y

(involves: BALB/cByJ * CD-1)
aciduria J:4165
Acadsdel-J/Acadsdel-J
Otcspf/Otc+

(involves: BALB/cByJ * CD-1)
aciduria J:4165
Acadsdel-J/Acadsdel-J
Otcspf/Otcspf

(involves: BALB/cByJ * CD-1)
oroticaciduria J:4165
AcadsHdlq8-C57BL/6J/AcadsHdlq8-C57BL/6J
(involves: C57BL/6J * NZB/BlNJ)
decreased circulating HDL cholesterol level J:84430
AcadsHdlq8-NZB/BlNJ/AcadsHdlq8-NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
increased circulating HDL cholesterol level J:84430
Acadvltm1Uab/Acadvltm1Uab
(involves: 129S6/SvEvTac * C57BL/6)
abnormal enzyme/coenzyme activity J:72193
abnormal lipid homeostasis J:72193
increased circulating carnitine level J:72193
Acadvltm1Vje/Acadvl+
(involves: 129/Sv * C57BL/6)
abnormal amino acid level J:102010
Acadvltm1Vje/Acadvltm1Vje
(involves: 129/Sv * C57BL/6)
abnormal amino acid level J:102010
impaired adaptive thermogenesis J:102010
impaired glucose tolerance J:102010
Acadvltm1Vje/Acadvltm1Vje
(involves: 129/Sv * Black Swiss * C57BL/6)
abnormal amino acid level J:106714
decreased glycogen level J:106714
hypoglycemia J:106714
impaired adaptive thermogenesis J:106714
Acadvltm1Zkhu/Acadvltm1Zkhu
Tg(Myh6-cre)1Jmk/0

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCr)
abnormal adaptive thermogenesis J:208711
decreased circulating glucose level J:208711
decreased core body temperature J:208711
decreased respiratory quotient J:208711
Acancmd/Acancmd
(involves: STOCK T tlow Itpr3tf)
polyhydramnios J:23353
Acantm1b(EUCOMM)Hmgu/Acan+
(C57BL/6N-Acantm1b(EUCOMM)Hmgu/H)
increased circulating HDL cholesterol level J:211773
Acap1tm1.1(KOMP)Vlcg/Acap1tm1.1(KOMP)Vlcg
(B6N(Cg)-Acap1tm1.1(KOMP)Vlcg/J)
decreased circulating glucose level J:211773
Acat2tm1b(KOMP)Wtsi/Acat2+
(C57BL/6N-Acat2tm1b(KOMP)Wtsi/Bay)
increased circulating chloride level J:211773
Acbd3tm1b(EUCOMM)Hmgu/Acbd3+
(C57BL/6N-Acbd3tm1b(EUCOMM)Hmgu/Ieg)
decreased circulating triglyceride level J:211773
increased circulating aspartate transaminase level J:211773
Acbd5tm1a(EUCOMM)Wtsi/Acbd5tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Acbd5tm1a(EUCOMM)Wtsi/WtsiCnbc)
abnormal ether lipid level J:299448
abnormal glycerol level J:299448
abnormal lipid homeostasis J:299448
increased fatty acids level J:299448
Acbd5tm1b(EUCOMM)Wtsi/Acbd5tm1b(EUCOMM)Wtsi
(C57BL/6N-Acbd5tm1b(EUCOMM)Wtsi/Wtsi)
decreased circulating calcium level J:211773
decreased circulating serum albumin level J:211773
decreased circulating total protein level J:211773
decreased circulating triglyceride level J:211773
improved glucose tolerance J:211773
increased blood urea nitrogen level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating creatinine level J:211773
Acdacd/Acdacd
(DW/J-Acdacd Pou1f1+)
abnormal adrenocorticotropin level J:18027
abnormal corticosterone level J:18027
abnormal pituitary hormone level J:18027
decreased circulating corticosterone level J:18027
increased adrenocorticotropin level J:18027
Acdtm1.1Blas/Acdtm1.1Blas
Tg(KRT5-cre)1Tak/?

(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL)
impaired skin barrier function J:160600
Ace2em1(ACE2)Yowa/Ace2em1(ACE2)Yowa
(C57BL/6-Ace2em1(ACE2)Yowa)
abnormal circulating cytokine level J:288243
increased circulating interferon-gamma level J:288243
increased circulating interleukin-9 level J:288243
Ace2em1Cya/Y
(C57BL/6-Ace2em1Cya)
intestinal edema J:299383
Ace2tm1Cof/Y
(129S6/SvEvTac-Ace2tm1Cof)
increased angiotensin II level J:113108
increased circulating angiotensin II level J:113108
Ace2tm1Cof/Ace2tm1Cof
(involves: 129S6/SvEvTac * C57BL/6)
abnormal corneal wound healing J:289503
Ace2tm1Hira/Y
(involves: 129S7/SvEvBrd * C57BL/6)
increased angiotensin II level J:135766
increased circulating angiotensin II level J:135766
Ace2tm1Lex/Ace2tm1Lex
(B6;129S5-Ace2tm1Lex/Mmucd)
abnormal enzyme/coenzyme activity J:264991
increased angiotensin I-converting enzyme activity J:264991
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:124548
increased NAD(P)H oxidase activity J:124548
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd)
abnormal susceptibility to injury induced morbidity/mortality J:100334
increased angiotensin II level J:100334
increased circulating angiotensin II level J:100334
increased susceptibility to injury J:100334
pulmonary edema J:100334
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6J)
pulmonary edema J:277074
Ace2tm1Pngr/Ace2tm1Pngr
(involves: 129P2/OlaHsd)
abnormal susceptibility to injury induced morbidity/mortality J:100334
increased angiotensin II level J:100334
increased circulating angiotensin II level J:100334
increased susceptibility to injury J:100334
pulmonary edema J:100334
Ace2tm1Pngr/Ace2tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6J)
pulmonary edema J:277074
Acetm1Keb/Acetm1Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal urine homeostasis J:33018
decreased urine aldosterone level J:33018
decreased urine osmolality J:33018
increased circulating creatinine level J:33018
increased urine potassium level J:33018
Acetm1Keb/Acetm1Keb
(involves: 129S1/Sv * 129X1/SvJ)
abnormal response/metabolism to endogenous compounds J:163902
increased renin activity J:163902
Acetm1Keb/Acetm5Keb
(involves: 129S1/Sv * 129X1/SvJ)
decreased angiotensin I-converting enzyme activity J:89512
increased circulating renin level J:89512
Acetm1Mcf/Acetm1Mcf
(Not Specified)
decreased urine osmolality J:32114
increased blood urea nitrogen level J:32114
Acetm1Unc/Ace+
(involves: 129P2/OlaHsd * C57BL/6J)
increased insulin secretion J:128859
Acetm1Unc/Ace+
(B6.129P2-Acetm1Unc)
homeostasis/metabolism phenotype J:72577
Acetm1Unc/Acetm1Unc
(involves: 129P2/OlaHsd)
decreased angiotensin II level J:100334
decreased circulating angiotensin II level J:100334
decreased susceptibility to injury J:100334
Acetm1Unc/Acetm1Unc
Ace2tm1Pngr/Y

(involves: 129P2/OlaHsd)
decreased angiotensin II level J:100334
decreased circulating angiotensin II level J:100334
decreased susceptibility to injury J:100334
Acetm1Unc/Acetm1Unc
Ace2tm1Pngr/Ace2tm1Pngr

(involves: 129P2/OlaHsd)
decreased angiotensin II level J:100334
decreased circulating angiotensin II level J:100334
decreased susceptibility to injury J:100334
Acetm2Keb/Acetm2Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased urine osmolality J:40475
Acetm3Unc/Ace+
(involves: 129P2/OlaHsd * C57BL/6J)
decreased insulin secretion J:128859
Acetm3Unc/Ace+
(B6.129P2-Acetm3Unc)
albuminuria J:72577
Acetm4Keb/Acetm4Keb
(involves: 129S1/Sv * 129X1/SvJ)
decreased urine osmolality J:83894
Acetm4Keb/Acetm4Keb
Bdkrb2tm1Jfh/Bdkrb2tm1Jfh

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)
abnormal response/metabolism to endogenous compounds J:83894
decreased urine osmolality J:83894
Acetm5Keb/Acetm5Keb
(involves: 129S1/Sv * 129X1/SvJ)
decreased angiotensin I-converting enzyme activity J:89512
homeostasis/metabolism phenotype J:163902
Acetm5Keb/Acetm5Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased sensitivity to xenobiotic induced morbidity/mortality J:163454
decreased susceptibility to injury J:163454
increased angiotensin I-converting enzyme activity J:163454
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6)
abnormal interleukin level J:122178
Acetm8.1Keb/Acetm8.1Keb
(involves: 129 * C57BL/6 * FVB/N)
abnormal angiotensin I-converting enzyme activity J:163902
abnormal circulating protein level J:163902
abnormal response/metabolism to endogenous compounds J:163902
decreased angiotensin I-converting enzyme activity J:163902
decreased circulating angiotensin II level J:163902
decreased urine osmolality J:163902
increased renin activity J:163902
Acetm8.1Keb/Acetm8.1Keb
(involves: 129 * C57BL/6)
decreased angiotensin I-converting enzyme activity J:163454
homeostasis/metabolism phenotype J:163454
Acetm8Keb/Acetm8Keb
(involves: 129)
abnormal homeostasis J:163902
Acetm9Keb/Acetm9Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal circulating angiotensinogen level J:185888
abnormal urine osmolality J:185888
decreased angiotensin I-converting enzyme activity J:185888
decreased circulating angiotensinogen level J:185888
decreased urine osmolality J:185888
homeostasis/metabolism phenotype J:185888
increased renin activity J:185888
Acer1tm1(KOMP)Vlcg/Acer1tm1(KOMP)Vlcg
(C57BL/6-Acer1tm1(KOMP)Vlcg)
abnormal enzyme/coenzyme activity J:252017
Acer1tm1a(EUCOMM)Wtsi/Acer1tm1a(EUCOMM)Wtsi
(C57BL/6N-Acer1tm1a(EUCOMM)Wtsi)
abnormal ceramide level J:235775
abnormal lipid level J:235775
abnormal sphingomyelin level J:235775
decreased sphingosine level J:235775
impaired skin barrier function J:235775
increased basal metabolism J:235775
increased energy expenditure J:235775
Acer2em1Mvw/Acer2em1Mvw
(C57BL/6J-Acer2em1Mvw/MvwJ)
abnormal sphingolipid level J:256650
Acer3tm1Cmao/Acer3tm1Cmao
(B6.129S6-Acer3tm1Cmao/Cmao)
abnormal ceramide level J:228886
abnormal sphingolipid level J:228886
abnormal sphingomyelin level J:228886
increased sphingosine level J:228886
Achetm1.1Hssh/Achetm1.1Hssh
(involves: 129S4/SvJae * C57BL/6)
abnormal body temperature homeostasis J:140622
decreased body temperature J:140622
Achetm1.1Pata/Achetm1.1Pata
(involves: 129X1/SvJ * C57BL/6)
abnormal platelet physiology J:132775
Achetm1.1Pata/Achetm1.1Pata
(involves: 129X1/SvJ)
decreased body temperature J:147483
increased physiological sensitivity to xenobiotic J:147483
Achetm1Loc/Achetm1Loc
(involves: 129S1/Sv * 129X1/SvJ)
abnormal physiological response to xenobiotic J:130048
increased physiological sensitivity to xenobiotic J:130048
increased sensitivity to xenobiotic induced morbidity/mortality J:130048
Achetm4.1Pata/Achetm4.1Pata
(involves: 129X1/SvJ * Black Swiss * C57BL/6 * FVB * FVB/N)
homeostasis/metabolism phenotype J:147855
Achetm4Pata/Achetm4Pata
(involves: 129X1/SvJ * Black Swiss * C57BL/6 * FVB)
impaired exercise endurance J:147855
Achetm4Pata/Achetm4Pata
(involves: 129X1/SvJ)
decreased body temperature J:147483
increased physiological sensitivity to xenobiotic J:147483
Achetm4Pata/Achetm4Pata
Prima1tm1Vebe/Prima1tm1Vebe

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
abnormal body temperature homeostasis J:147425
Ackr1tm1Scp/Ackr1tm1Scp
(involves: 129P2/OlaHsd)
abnormal circulating chemokine level J:162629
Ackr1tm1Skmz/Ackr1tm1Skmz
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal chemokine level J:82938
abnormal homeostasis J:82938
Ackr3tm1.1Twb/Ackr3tm1.1Twb
(involves: 129S/SvEv * BALB/cJ * C57BL/6)
cyanosis J:167833
Ackr3tm1Jgo/Ackr3tm1Jgo
(involves: 129S/SvEvBrd * C57BL/6)
abnormal atrial thrombosis J:136246
Ackr4tm1.1Rjbn/Ackr4tm1.1Rjbn
(B6.129S6-Ackr4tm1.1Rjbn)
abnormal chemokine level J:166490
abnormal circulating chemokine level J:166490
AclyGt(NPX098)Byg/Acly+
(involves: 129P2/OlaHsd * C57BL/6)
homeostasis/metabolism phenotype J:88490
Acmsdtm1b(EUCOMM)Hmgu/Acmsdtm1b(EUCOMM)Hmgu
(C57BL/6N-Acmsdtm1b(EUCOMM)Hmgu/Ieg)
decreased circulating bilirubin level J:211773
Aco1tm1Roua/Aco1tm1Roua
(involves: C57BL/6)
abnormal iron homeostasis J:87889
Acot5tm1a(KOMP)Wtsi/Acot5tm1a(KOMP)Wtsi
(C57BL/6N-Acot5tm1a(KOMP)Wtsi/Wtsi)
increased circulating triglyceride level J:211773
Acot7tm1.1Mwol/Acot7tm1.1Mwol
Tg(Nes-cre)1Kln/0

(involves: C57BL/6 * SJL)
abnormal circulating lipid level J:203753
abnormal glucose homeostasis J:203753
abnormal lipid homeostasis J:203753
abnormal phospholipid level J:203753
decreased susceptibility to induced hypothermia J:203753
increased circulating free fatty acids level J:203753
increased circulating triglyceride level J:203753
increased energy expenditure J:203753
increased fatty acids level J:203753
increased liver triglyceride level J:203753
increased triglyceride level J:203753
Acot11tm1Deco/Acot11tm1Deco
(involves: 129S6/SvEvTac * C57BL/6)
decreased circulating cholesterol level J:182660
decreased circulating glucose level J:182660
decreased circulating HDL cholesterol level J:182660
decreased physiological sensitivity to xenobiotic J:182660
decreased susceptibility to diet-induced obesity J:182660
homeostasis/metabolism phenotype J:182660
improved glucose tolerance J:182660
increased circulating triglyceride level J:182660
increased energy expenditure J:182660
increased fatty acid oxidation J:182660
increased fatty acids level J:182660
increased oxygen consumption J:182660
increased respiratory quotient J:182660
Acot13tm1Deco/Acot13tm1Deco
(involves: 129 * C57BL/6)
abnormal enzyme/coenzyme activity J:183258
abnormal gluconeogenesis J:183258
abnormal glucose homeostasis J:183258
abnormal lipid level J:183258
decreased basal metabolism J:183258
decreased circulating free fatty acids level J:183258
decreased circulating ketone body level J:183258
decreased liver cholesterol level J:183258
decreased liver triglyceride level J:183258
decreased oxygen consumption J:183258
decreased respiratory quotient J:183258
improved glucose tolerance J:183258
Acot13tm1Deco/Acot13tm1Deco
(Not Specified)
abnormal adaptive thermogenesis J:204997
abnormal circadian temperature homeostasis J:204997
increased core body temperature J:204997
increased energy expenditure J:204997
increased oxygen consumption J:204997
increased respiratory quotient J:204997
Acox1em1Wum/Acox1em1Wum
Tg(Adipoq-cre)1Evdr/0

(involves: FVB/NJ)
homeostasis/metabolism phenotype J:270463
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
increased circulating alanine transaminase level J:174942
increased circulating alkaline phosphatase level J:174942
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J)
hyperlipidemia J:35794
Acox3em1(IMPC)J/Acox3em1(IMPC)J
(C57BL/6NJ-Acox3em1(IMPC)J/Mmjax)
impaired glucose tolerance J:211773
Acoxlem1(IMPC)Mbp/Acoxlem1(IMPC)Mbp
(C57BL/6NCrl-Acoxlem1(IMPC)Mbp/Mmucd)
improved glucose tolerance J:211773
Acp1Gt(RRK222)Byg/Acp1Gt(RRK222)Byg
(C.129P2(B6)-Acp1Gt(RRK222)Byg)
decreased response of heart to induced stress J:227733
Acsbg1tm1Mld/Acsbg1tm1Mld
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased fatty acids level J:150391
increased circulating testosterone level J:150391
increased fatty acids level J:150391
Acsl1tm1Rcol/Acsl1tm1Rcol
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
abnormal lipid homeostasis J:155714
homeostasis/metabolism phenotype J:155714
Acsl1tm1Rcol/Acsl1tm1Rcol
Tg(Fabp4-cre)1Rev/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating glycerol level J:162996
decreased fatty acid oxidation J:162996
decreased lipoprotein lipase activity J:162996
hyperlipidemia J:162996
hypoglycemia J:162996
impaired adaptive thermogenesis J:162996
increased circulating free fatty acids level J:162996
increased circulating triglyceride level J:162996
increased fatty acids level J:162996
increased triglyceride level J:162996
Acsl4tm1Tty/Acsl4+
(involves: C57BL/6NCrj * CBA/JNCrj)
homeostasis/metabolism phenotype J:70023
increased prostaglandin level J:70023
Acsl5tm1.1(KOMP)Vlcg/Acsl5tm1.1(KOMP)Vlcg
(C57BL/6N-Acsl5tm1.1(KOMP)Vlcg/Ucd)
decreased circulating cholesterol level J:211773
decreased circulating glucose level J:211773
decreased circulating HDL cholesterol level J:211773
decreased circulating total protein level J:211773
decreased circulating triglyceride level J:211773
increased circulating bilirubin level J:211773
Acsl6tm1.1Jeme/Acsl6tm1.1Jeme
(involves: BALB/cJ * C57BL/6)
abnormal amino acid metabolism J:267563
abnormal carbohydrate metabolism J:267563
abnormal lipogenesis J:267563
abnormal nucleotide metabolism J:267563
decreased lipogenesis J:267563
homeostasis/metabolism phenotype J:267563
increased lipogenesis J:267563
Acsl6tm1Jeme/Acsl6tm1Jeme
Tg(Gfap-cre)77.6Mvs/0

(involves: BALB/cJ * C57BL/6)
decreased lipogenesis J:267563
Acsm2tm1.1(KOMP)Vlcg/Acsm2tm1.1(KOMP)Vlcg
(B6N(Cg)-Acsm2tm1.1(KOMP)Vlcg/J)
decreased circulating chloride level J:211773
decreased circulating glucose level J:211773
Acss1tm1Jsak/Acss1tm1Jsak
(B6.129-Acss1tm1Jsak)
abnormal blood homeostasis J:146647
abnormal body temperature homeostasis J:146647
abnormal carbon dioxide level J:146647
abnormal circulating free fatty acids level J:146647
abnormal exercise endurance J:146647
decreased circulating leptin level J:146647
hypoglycemia J:146647
impaired adaptive thermogenesis J:146647
Acta1tm1Jll/Acta1tm1Jll
(involves: 129P2/OlaHsd * Black Swiss)
decreased glycogen level J:78070
decreased liver glycogen level J:78070
decreased skeletal muscle glycogen level J:78070
Actbtm1(INSR)Dac/Actbtm1(INSR)Dac
Insrtm1Dac/Insrtm1Dac

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased circulating ketone body level J:91350
Actbtm1(INSR)Dac/Actbtm1(INSR)Dac
Insrtm1Dac/Insrtm1Dac
Tg(Camk2a-cre)#Szi/?

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J * CBA)
increased circulating glucose level J:91350
increased circulating insulin level J:91350
Actbtm1(INSR)Dac/Actbtm1(INSR)Dac
Insrtm1Dac/Insrtm1Dac
Tg(Hsp70-1-cre)6Arge/?

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
increased circulating glucose level J:91350
increased circulating insulin level J:91350
Actbtm1(INSR)Dac/Actbtm1(INSR)Dac
Insrtm1Dac/Insrtm1Dac
Tg(Nes-cre)1Kln/?

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * SJL)
increased circulating glucose level J:91350
increased circulating insulin level J:91350
Actbtm1(INSR)Dac/Actbtm1(INSR)Dac
Insrtm1Dac/Insrtm1Dac
Tg(Syn1-cre)671Jxm/?

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
increased circulating glucose level J:91350
increased circulating insulin level J:91350
Actbtm3.1(Sirt1)Npa/Actb+
(involves: 129/Sv * C57BL/6 * C57BL/6J)
decreased circulating adiponectin level J:160212
decreased circulating cholesterol level J:160212
decreased circulating free fatty acids level J:160212
decreased circulating HDL cholesterol level J:160212
decreased circulating insulin level J:160212
decreased circulating LDL cholesterol level J:160212
decreased circulating leptin level J:160212
decreased fasting circulating glucose level J:160212
homeostasis/metabolism phenotype J:160212
improved glucose tolerance J:160212
increased oxygen consumption J:160212
Actbtm4(cre/ERT2)Npa/Actb+
Sgpl1tm1.1Npa/Sgpl1tm1.1Npa

(involves: BALB/cJ * C57BL/6)
abnormal lipid homeostasis J:199525
Actc1tm1Jll/Actc1tm1Jll
Tg(Myh6-Actg2)1Jll/0

(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
abnormal cardiac thrombosis J:40165
Actl10tm1a(EUCOMM)Wtsi/Actl10tm1a(EUCOMM)Wtsi
(C57BL/6N-Actl10tm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating fructosamine level J:211773
Actn3tm1Knno/Actn3tm1Knno
(involves: 129 * 129S1/Sv * 129X1/SvJ)
increased aerobic running capacity J:125639
Actn4tm1.1Plk/Actn4tm1.1Plk
(involves: 129S4/SvJae * 129X1/SvJ)
increased urine protein level J:90755
Actn4tm1a(EUCOMM)Wtsi/Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
hemopericardium J:239583
subcutaneous edema J:239583
Actn4tm1Plk/Actn4tm1Plk
(involves: 129 * C57BL/6)
abnormal blood urea nitrogen level J:83911
albuminuria J:118122, J:83911
increased urine microalbumin level J:83911
increased urine protein level J:90755
Actr6tm1a(EUCOMM)Wtsi/Actr6+
(C57BL/6N-Actr6tm1a(EUCOMM)Wtsi/Wtsi)
increased circulating glycerol level J:211773
Actr8tm1.1(KOMP)Vlcg/Actr8+
(B6N(Cg)-Actr8tm1.1(KOMP)Vlcg/J)
increased circulating sodium level J:211773
Acvr1tm1.1(KOMP)Vlcg/Acvr1+
(C57BL/6N-Acvr1tm1.1(KOMP)Vlcg/MbpMmucd)
increased circulating total protein level J:211773
Acvr1tm1Emsh/Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
edema J:194134
Acvr1tm1Glh/Acvr1+
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Pdgfra-cre)1Clc/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N)
abnormal response to injury J:257905
Acvr1tm1Glh/Acvr1+
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0

(involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)
abnormal response to injury J:257905
Acvr1tm1Glh/Acvr1tm1Vk
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
abnormal response to injury J:257905
Acvr2atm1Zuk/Acvr2atm1Zuk
(either: 129 or (involves: 129S7/SvEvBrd * C57BL/6))
suppressed circulating follicle stimulating hormone level J:23924
Acvr2btm1Enl/Acvr2btm1Enl
(either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C57BL/6J))
cyanosis J:42018
Acvrl1tm1Dgen/Acvrl1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
pericardial effusion J:186473
Acvrl1tm1Enl/Acvrl1+
(B6.Cg-Acvrl1tm1Enl)
abnormal enzyme/coenzyme activity J:226550
abnormal physiological response to xenobiotic J:226550
decreased circulating angiotensin II level J:226550
increased circulating adrenaline level J:226550
increased circulating noradrenaline level J:226550
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo
Tg(Tal1-cre/ERT)1Jrg/0

(involves: 129 * C57BL/6)
abnormal vascular wound healing J:227170
Ad/Ad
(involves: Chr 7 marker stock * Wild stock)
abnormal protein level J:6095
increased circulating insulin level J:6095
Ad/Ad+
(involves: Chr 7 marker stock * Wild stock)
abnormal protein level J:6095
increased circulating insulin level J:6095
Adatm1Mw/Adatm1Mw
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal enzyme/coenzyme level J:25085
abnormal nucleotide metabolism J:25085
cyanosis J:25085
decreased circulating serum albumin level J:25085
decreased circulating total protein level J:25085
Adatm1Mw/Adatm1Mw
Tg(Afp-ADA)#Xiay/0

(involves: 129S7/SvEvBrd * C3H/HeJ * C57BL/6J)
increased urine protein level J:234143
Adatm1Vlr/Adatm1Vlr
(either: 129P2/OlaHsd-Adatm1Vlr or (involves: (129P2/OlaHsd * FVB/N))
cyanosis J:26731
Adad1em1(IMPC)J/Adad1+
(C57BL/6NJ-Adad1em1(IMPC)J/J)
decreased circulating chloride level J:211773
decreased circulating iron level J:211773
Adam8tm1.1Rood/Adam8tm1.1Rood
(involves: 129/Sv * C57BL/6 * FVB/N)
abnormal response/metabolism to endogenous compounds J:172936
Adam9tm1Bbl/Adam9tm1Bbl
(involves: 129)
enhanced wound healing J:161698
Adam10tm1Beni/Adam10tm1Beni
Adam17tm1.1Srj/Adam17tm1.1Srj
Tg(Pf4-icre)Q3Rsko/0

(involves: 129/Sv * 129S/SvEv * C57BL/6)
abnormal platelet physiology J:165863
Adam10tm1Beni/Adam10tm1Beni
Tg(Pf4-icre)Q3Rsko/0

(involves: 129/Sv * C57BL/6)
abnormal platelet physiology J:165863
Adam17m1Btlr/Adam17m1Btlr
(C57BL/6J-Adam17m1Btlr)
decreased circulating tumor necrosis factor level J:166602
decreased transforming growth factor beta level J:166602
Adam17tm1.1Srj/Adam17tm1.1Srj
(involves: 129S/SvEv * C57BL/6 * SJL)
abnormal chemokine level J:163380
Adam17tm1.1Srj/Adam17tm1.1Srj
(involves: 129S/SvEv)
abnormal platelet physiology J:165863
Adam17tm1.2Bbl/Adam17tm1.2Bbl
Sox9tm3(cre)Crm/Sox9+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
increased circulating interleukin-17 level J:144795
Adam17tm1.2Bbl/Adam17tm1.2Bbl
Sox9tm3(cre)Crm/Sox9+

(B6.129(SJL)-Sox9tm3(cre)Crm Adam17tm1.2Bbl)
abnormal circulating chemokine level J:229771
impaired skin barrier function J:229771
Adam17tm1Bbl/Adam17tm1Bbl
Lyz2tm1(cre)Ifo/0

(involves: 129P2/OlaHsd)
decreased circulating tumor necrosis factor level J:139846
Adam17tm1Bbl/Adam17tm1Bbl
Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased circulating tumor necrosis factor level J:139846
Adam17tm1Imx/Adam17tm1Imx
(involves: 129 * C57BL/6J)
edema J:166217
Adam17tm1Imx/Adam17tm1Imx
(involves: 129 * DBA/1J)
cyanosis J:68672
Adam17tm1Imx/Adam17tm1Imx
(B6.129-Adam17tm1Imx)
decreased physiological sensitivity to xenobiotic J:174865
Adam17tm1Rain/Adam17tm1Rain
(involves: C57BL/6)
decreased physiological sensitivity to xenobiotic J:174865
Adam19Gt(Betageo)1Bbl/Adam19Gt(Betageo)1Bbl
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
edema J:87592
Adam26atm1.1(KOMP)Vlcg/Adam26atm1.1(KOMP)Vlcg
(C57BL/6N-Adam26atm1.1(KOMP)Vlcg/Ucd)
increased blood urea nitrogen level J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating calcium level J:211773
increased circulating cholesterol level J:211773
increased circulating creatinine level J:211773
increased circulating glucose level J:211773
increased circulating phosphate level J:211773
increased circulating serum albumin level J:211773
increased circulating total protein level J:211773
Adam26atm1.1(KOMP)Vlcg/Adam26atm1.1(KOMP)Vlcg
(C57BL/6N-Adam26atm1.1(KOMP)Vlcg/MbpMmucd)
decreased bronchoconstrictive response J:211773
Adam33tm1b(EUCOMM)Hmgu/Adam33tm1b(EUCOMM)Hmgu
(C57BL/6N-Adam33tm1b(EUCOMM)Hmgu/Ieg)
increased circulating creatinine level J:211773
increased circulating potassium level J:211773
Adamdec1tm1Dgen/Adamdec1tm1Dgen
(B6.129P2-Adamdec1tm1Dgen)
decreased circulating interleukin-10 level J:301741
increased circulating interleukin-1 beta level J:301741
increased circulating interleukin-6 level J:301741
Adamts1em1(IMPC)Mbp/Adamts1+
(C57BL/6N-Adamts1em1(IMPC)Mbp/MbpMmucd)
increased circulating bilirubin level J:211773
Adamts1tm1Hku/Adamts1tm1Hku
(involves: 129S6/SvEvTac * C57BL/6)
decreased urine chloride ion level J:62260
decreased urine potassium level J:62260
decreased urine sodium level J:62260
homeostasis/metabolism phenotype J:62260
Adamts2tm1Prc/Adamts2tm1Prc
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal homeostasis J:271185
homeostasis/metabolism phenotype J:271185
Adamts3tm1.2Itl/Adamts3tm1.2Itl
(involves: BALB/cJ * C57BL/6NTac * SJL)
skin edema J:245044
Adamts3tm1b(KOMP)Wtsi/Adamts3tm1b(KOMP)Wtsi
(C57BL/6N-Adamts3tm1b(KOMP)Wtsi/Wtsi)
hemopericardium J:239583
retropleural edema J:239583
subcutaneous edema J:239583
Adamts6b2b1879.1Clo/Adamts6b2b1879.1Clo
(C57BL/6J-Adamts6b2b1879.1Clo)
hydrops fetalis J:175213
Adamts6b2b2029Clo/Adamts6b2b2029Clo
(C57BL/6J-Adamts6b2b2029Clo)
hydrops fetalis J:175213
Adamts6b2b2182Clo/Adamts6b2b2182Clo
(C57BL/6J-Adamts6b2b2182Clo)
hydrops fetalis J:175213
Adamts6b2b2187.1Clo/Adamts6b2b2187.1Clo
(C57BL/6J-Adamts6b2b2187.1Clo)
hydrops fetalis J:175213
Adamts6b2b2228Clo/Adamts6b2b2228Clo
(C57BL/6J-Adamts6b2b2228Clo)
hydrops fetalis J:175213
Adamts6b2b2405Clo/Adamts6b2b2405Clo
(C57BL/6J-Adamts6b2b2405Clo)
hydrops fetalis J:175213
Adamts6b2b2407Clo/Adamts6b2b2407Clo
(C57BL/6J-Adamts6b2b2407Clo)
hydrops fetalis J:175213
Adamts6b2b2744Clo/Adamts6b2b2744Clo
(C57BL/6J-Adamts6b2b2744Clo)
hydrops fetalis J:175213
Adamts6b2b2966.2Clo/Adamts6b2b2966.2Clo
(C57BL/6J-Adamts6b2b2966.2Clo)
hydrops fetalis J:175213
Adamts6em1(IMPC)Mbp/Adamts6em1(IMPC)Mbp
(C57BL/6N-Adamts6em1(IMPC)Mbp/MbpMmucd)
edema J:211773
Adamts7tm1a(KOMP)Wtsi/Adamts7tm1a(KOMP)Wtsi
(involves: C57BL/6N)
abnormal triglyceride level J:230573
abnormal vascular wound healing J:230573
homeostasis/metabolism phenotype J:230573
increased oxygen consumption J:230573
Adamts7tm1a(KOMP)Wtsi/Adamts7tm1a(KOMP)Wtsi
(C57BL/6-Adamts7tm1a(KOMP)Wtsi)
abnormal response to injury J:221183
increased collagen level J:221183
Adamts13s/Adamts13s
(129.B6-Adamts13s)
increased susceptibility to induced thrombosis J:148975
Adamts13tm1Dgi/Adamts13tm1Dgi
(involves: 129X1/SvJ * C57BL/6J * CASA/Rk)
abnormal platelet physiology J:101752
abnormal thrombosis J:101752
homeostasis/metabolism phenotype J:101752
increased circulating von Willebrand factor level J:101752
Adamts13tm1Dgi/Adamts13tm1Dgi
(B6.129X1-Adamts13tm1Dgi)
increased susceptibility to induced thrombosis J:133469
Adamts13tm1Dgi/Adamts13tm1Dgi
Vwftm1Wgr/Vwftm1Wgr

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CASA/Rk)
decreased physiological sensitivity to xenobiotic J:133469
decreased sensitivity to xenobiotic induced morbidity/mortality J:133469
Adamts13tm1Dgi/Adamts13tm1Dgi
Vwftm1Wgr/Vwftm1Wgr

(B6.129-Adamts13tm1Dgi Vwftm1Wgr)
decreased susceptibility to induced thrombosis J:133469
homeostasis/metabolism phenotype J:133469
Adamts13tm1Myta/Adamts13tm1Myta
(involves: 129S6/SvEvTac)
abnormal blood coagulation J:125786
abnormal platelet activation J:125786
abnormal thrombosis J:125786
Adamts14Gt(511E11)Cmhd/Adamts14Gt(511E11)Cmhd
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
homeostasis/metabolism phenotype J:271185
Adamts14Gt(511E11)Cmhd/Adamts14Gt(511E11)Cmhd
Adamts2tm1Prc/Adamts2tm1Prc

(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal homeostasis J:271185
homeostasis/metabolism phenotype J:271185
Adamts16em1(IMPC)H/Adamts16em1(IMPC)H
(C57BL/6N-Adamts16em1(IMPC)H/H)
decreased circulating potassium level J:211773
increased circulating HDL cholesterol level J:211773
Adamts17tm1.2Taks/Adamts17tm1.2Taks
(involves: C57BL * C57BL/6 * DBA)
increased collagen level J:295274
Adamts18tm1.1Wzha/Adamts18tm1.1Wzha
(involves: 129 * C57BL/6)
increased incidence of tumors by chemical induction J:258487
increased physiological sensitivity to xenobiotic J:258487
Adamtsl2tm1b(KOMP)Wtsi/Adamtsl2tm1b(KOMP)Wtsi
(C57BL/6-Adamtsl2tm1b(KOMP)Wtsi)
cyanosis J:221347
Adamtsl5tm1b(EUCOMM)Hmgu/Adamtsl5tm1b(EUCOMM)Hmgu
(C57BL/6N-Adamtsl5tm1b(EUCOMM)Hmgu/H)
decreased fasting circulating glucose level J:211773
Adarem1Stsn/Adartm1Olds
(involves: 129S/SvEv * C57BL/6J)
abnormal homeostasis J:308678
decreased circulating serum albumin level J:308678
increased circulating alkaline phosphatase level J:308678
Adarem1Stsn/Adartm1Olds
Dhx58tm1Itl/Dhx58tm1Itl

(involves: 129S/SvEv * C57BL/6J * C57BL/6NTac)
homeostasis/metabolism phenotype J:308678
Adarem1Stsn/Adartm1Olds
Eif2ak2tm1Jcbe/Eif2ak2tm1Jcbe

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J)
abnormal homeostasis J:308678
homeostasis/metabolism phenotype J:308678
Adarem1Stsn/Adartm1Olds
Ifih1tm1.1Cln/Ifih1tm1.1Cln

(involves: 129S/SvEv * 129X1/SvJ * C57BL/6J)
homeostasis/metabolism phenotype J:308678
Adarem1Stsn/Adartm1Olds
Ifnar1tm1Agt/Ifnar1tm1Agt

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
homeostasis/metabolism phenotype J:308678
Adartm1b(EUCOMM)Wtsi/Adar+
(B6N(Cg)-Adartm1b(EUCOMM)Wtsi/J)
decreased circulating glucose level J:211773
Adartm1Knk/Adartm1Knk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
abnormal circulating enzyme level J:87714
hyperglycemia J:87714
increased circulating alanine transaminase level J:87714
increased circulating alkaline phosphatase level J:87714
increased circulating aspartate transaminase level J:87714
increased circulating lactate dehydrogenase level J:87714
Adartm2Phs/Adartm2Phs
(B6.Cg-Adartm2Phs)
abnormal circulating interferon-beta level J:142338
increased circulating interferon-alpha level J:142338
Adck2tm1(KOMP)Vlcg/Adck2+
(C57BL/6-Adck2tm1(KOMP)Vlcg)
abnormal enzyme/coenzyme level J:280282
abnormal homeostasis J:280282
decreased circulating carnitine level J:280282
decreased circulating free fatty acids level J:280282
decreased fatty acid beta-oxidation J:280282
decreased glycerol level J:280282
impaired exercise endurance J:280282
increased carbon dioxide production J:280282
increased circulating lactate level J:280282
increased fatty acids level J:280282
increased liver free fatty acids level J:280282
increased oxygen consumption J:280282
increased respiratory quotient J:280282
organic aciduria J:280282
Adck2tm1.1(KOMP)Vlcg/Adck2tm1.1(KOMP)Vlcg
(B6N(Cg)-Adck2tm1.1(KOMP)Vlcg/J)
increased circulating potassium level J:211773
Adcy1tm1b(EUCOMM)Wtsi/Adcy1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adcy1tm1b(EUCOMM)Wtsi/H)
increased circulating creatine kinase level J:211773
increased circulating phosphate level J:211773
Adcy1tm1Drs/Adcy1tm1Drs
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal enzyme/coenzyme activity J:22287
Adcy2tm1a(KOMP)Wtsi/Adcy2tm1a(KOMP)Wtsi
(C57BL/6N-Adcy2tm1a(KOMP)Wtsi/Wtsi)
increased circulating HDL cholesterol level J:211773
Adcy3Jll/Adcy3+
(C57BL/6J-Adcy3Jll)
decreased susceptibility to diet-induced obesity J:223554
Adcy3Jll/Adcy3+
(involves: 129S1/SvImJ * C57BL/6J)
decreased circulating glucose level J:223554
decreased circulating insulin level J:223554
decreased circulating leptin level J:223554
decreased susceptibility to diet-induced obesity J:223554
increased oxygen consumption J:223554
Adcy3Jll/Adcy3Jll
(involves: 129S1/SvImJ * C57BL/6J)
decreased susceptibility to diet-induced obesity J:223554
Adcy3tm1.1Dek/Adcy3tm1.1Dek
Adcy6tm1.1Dek/Adcy6tm1.1Dek
Tg(AQP2-cre)2Dek/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
decreased urine osmolality J:207417
decreased urine potassium level J:207417
decreased urine sodium level J:207417
Adcy3tm1Drs/Adcy3tm1Drs
(involves: 129X1/SvJ * C57BL/6)
decreased circulating renin level J:144961
homeostasis/metabolism phenotype J:144961
increased circulating creatinine level J:144961
Adcy3tm2.1Drs/Adcy3tm2.1Drs
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+

(involves: 129 * 129X1/SvJ * C57BL/6)
increased circulating corticosterone level J:281839
Adcy5tm1Yish/Adcy5tm1Yish
(involves: 129X1/SvJ * C57BL/6)
abnormal enzyme/coenzyme activity J:83301
Adcy6tm1.1(KOMP)Vlcg/Adcy6tm1.1(KOMP)Vlcg
(C57BL/6N-Adcy6tm1.1(KOMP)Vlcg/Ucd)
increased blood urea nitrogen level J:211773
increased circulating alkaline phosphatase level J:211773
Adcy6tm1.1Dek/Adcy6tm1.1Dek
Tg(Aqp2-cre)1Dek/0

(involves: 129X1/SvJ * C57BL/6 * SJL)
decreased urine osmolality J:180012
Adcy6tm1Hkh/Adcy6tm1Hkh
(involves: 129S1/Sv * 129X1/SvJ)
abnormal calcium ion homeostasis J:143138
Adcy6tm1Yich/Adcy6tm1Yich
(involves: 129S6/SvEvTac)
abnormal renal water reabsorption J:161317
decreased urine chloride ion level J:161317
decreased urine osmolality J:161317
decreased urine potassium level J:161317
decreased urine sodium level J:161317
decreased urine urea nitrogen level J:161317
Adcy6tm2Yich/Adcy6tm2Yich
(involves: 129S6/SvEvTac)
abnormal renal water reabsorption J:161317
decreased urine chloride ion level J:161317
decreased urine creatinine level J:161317
decreased urine osmolality J:161317
decreased urine potassium level J:161317
decreased urine sodium level J:161317
decreased urine urea nitrogen level J:161317
Adcy8tm1Ljm/Adcy8tm1Ljm
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal corticosterone level J:63173
abnormal enzyme/coenzyme activity J:63173
Adcy9tm1b(EUCOMM)Wtsi/Adcy9+
(C57BL/6N-Adcy9tm1b(EUCOMM)Wtsi/Wtsi)
decreased circulating chloride level J:211773
increased circulating insulin level J:211773
Adcy9tm1b(EUCOMM)Wtsi/Adcy9tm1b(EUCOMM)Wtsi
(C57BL/6N-Adcy9tm1b(EUCOMM)Wtsi/Wtsi)
retropleural edema J:239583
Adcy10tm1Lex/Adcy10tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased circulating cholesterol level J:103485
increased triglyceride level J:103485
Adcyap1tm1Clw/Adcyap1tm1Clw
(B6.129S4-Adcyap1tm1Clw)
increased susceptibility to dopaminergic neuron neurotoxicity J:194151
Adcyap1tm1Eid/Adcyap1tm1Eid
(involves: 129S4/SvJae * C57BL/6)
decreased adrenaline level J:73702
decreased circulating adrenaline level J:73702
hypoglycemia J:73702
Adcyap1tm1Nms/Adcyap1tm1Nms
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6) or (involves: C57BL/6))
decreased liver glycogen level J:71968
hypoglycemia J:71968
impaired adaptive thermogenesis J:79468
increased circulating cholesterol level J:71968
increased circulating corticosterone level J:71968
increased circulating free fatty acids level J:71968
increased circulating insulin level J:71968
increased circulating ketone body level J:71968
increased circulating triglyceride level J:71968
Adcyap1tm1Nms/Adcyap1tm1Nms
(B6.129-Adcyap1tm1Nms)
decreased circulating progesterone level J:131950
decreased circulating prolactin level J:131950
Adcyap1r1tm1Bbt/Adcyap1r1tm1Bbt
(involves: 129 * C57BL/6J)
decreased circulating insulin level J:62115
impaired glucose tolerance J:62115
increased circulating insulin level J:62115
Add1tm1Llp/Add1tm1Llp
(involves: 129P2/OlaHsd * 129S1/SvImJ * C57BL/6J)
homeostasis/metabolism phenotype J:138919
Add2tm1Feb/Add2tm1Feb
(B6.129-Add2tm1Feb)
increased circulating bilirubin level J:63047
Add2tm1Llp/Add2tm1Llp
(involves: 129S4/SvJae * C57BL/6J)
increased kidney iron level J:71029
increased liver iron level J:71029
increased spleen iron level J:71029
Adgra1tm1b(EUCOMM)Hmgu/Adgra1tm1b(EUCOMM)Hmgu
(B6N(Cg)-Adgra1tm1b(EUCOMM)Hmgu/J)
improved glucose tolerance J:211773
Adgrb1tm1Egvm/Adgrb1tm1Egvm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal protein level J:222100
Adgrb1tm2a(EUCOMM)Wtsi/Adgrb1tm2a(EUCOMM)Wtsi
(C57BL/6N-Adgrb1tm2a(EUCOMM)Wtsi/Wtsi)
decreased circulating serum albumin level J:211773
increased circulating chloride level J:211773
increased circulating insulin level J:211773
Adgrb2tm1b(KOMP)Mbp/Adgrb2tm1b(KOMP)Mbp
(B6N(Cg)-Adgrb2tm1b(KOMP)Mbp/J)
decreased fasting circulating glucose level J:211773
Adgrf5m1Btlr/Adgrf5m1Btlr
(C57BL/6J-Adgrf5m1Btlr)
increased circulating glucose level J:225045
Adgrf5tm1.1Bstc/Adgrf5tm1.2Bstc
Tg(Sftpc-cre)1Blh/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
pulmonary alveolar proteinosis J:196943
Adgrf5tm1.1Bstc/Adgrf5tm1.2Bstc
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
abnormal lipid level J:196943
increased cholesterol level J:196943
Adgrf5tm1.2Bstc/Adgrf5tm1.2Bstc
(involves: 129S4/SvJae * C57BL/6J)
abnormal lipid level J:196943
increased cholesterol level J:196943
pulmonary alveolar proteinosis J:196943
Adgrf5tm1b(KOMP)Wtsi/Adgrf5tm1b(KOMP)Wtsi
(C57BL/6N-Adgrf5tm1b(KOMP)Wtsi/Tcp)
decreased circulating cholesterol level J:211773
increased circulating bilirubin level J:211773
increased fasting circulating glucose level J:211773
Adgrg2tm1Bend/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal fluid regulation J:93019
Adgrg5tm1b(EUCOMM)Wtsi/Adgrg5tm1b(EUCOMM)Wtsi
(C57BL/6N-Adgrg5tm1b(EUCOMM)Wtsi/BayMmucd)
increased circulating amylase level J:211773
Adgrg6tm1Apr/Adgrg6tm1Apr
(either: 129S/SvEv-Gpr126tm1Apr or B6.129S-Gpr126tm1Apr or (involves: 129S/SvEv * MF1))
edema J:167309
Adgrg6tm1Taki/Adgrg6tm1Taki
(involves: C57BL/6)
increased cardiac muscle triglyceride level J:202002
pericardial edema J:202002
Adgrl3Gt(S17-5H1)Sor/Adgrl3Gt(S17-5H1)Sor
(involves: 129S4/SvJaeSor * C57BL/6)
decreased circulating calcium level J:259247
increased dopamine level J:185872
increased serotonin level J:185872
Adh1tm1Gdu/Adh1tm1Gdu
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal ethanol metabolism J:55555
abnormal retinol metabolism J:85538, J:55555, J:76746
Adh1tm2Gdu/Adh1tm2Gdu
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal retinol metabolism J:76055
Adh1tm2Gdu/Adh1tm2Gdu
Adh7tm1Gdu/Adh7tm1Gdu

(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal retinol metabolism J:76055
Adh5tm1.1Llli/Adh5tm1.1Llli
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(B6.Cg-Adh5tm1.1Llli Speer6-ps1Tg(Alb-cre)21Mgn)
increased sensitivity to xenobiotic induced morbidity/mortality J:173666
Adh5tm1Gdu/Adh5tm1Gdu
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
increased sensitivity to xenobiotic induced morbidity/mortality J:55555
Adh5tm1Stam/Adh5tm1Stam
(B6.129-Adh5tm1Stam)
abnormal metabolism J:88337
increased physiological sensitivity to xenobiotic J:88337
Adh5tm1Stam/Adh5tm1Stam
(involves: 129)
increased sensitivity to xenobiotic induced morbidity/mortality J:173666
Adh7tm1Gdu/Adh7tm1Gdu
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal ethanol metabolism J:56168, J:55555
abnormal retinol metabolism J:76055, J:56168
abnormal vitamin A level J:55555
Adh7tm1Gdu/Adh7tm1Gdu
(B6.129(Cg)-Adh7tm1Gdu)
increased dopamine level J:167234
Adigtm1.1(KOMP)Vlcg/Adigtm1.1(KOMP)Vlcg
(B6J.B6N-Adigtm1.1(KOMP)Vlcg)
decreased circulating insulin level J:304292
decreased circulating leptin level J:304292
decreased susceptibility to diet-induced obesity J:304292
homeostasis/metabolism phenotype J:304292
improved glucose tolerance J:304292
increased energy expenditure J:304292
increased insulin sensitivity J:304292
Adigtm1.1(KOMP)Vlcg/Adigtm1.1(KOMP)Vlcg
Lepob/Lepob

(B6.Cg-Adigtm1.1(KOMP)Vlcg Lepob)
impaired glucose tolerance J:304292
Adip1LG/J/?
Capn10tm1Chev/Capn10+

((B6.129-Capn10tm1Chev x LG/J)F1)
decreased circulating cholesterol level J:153477
decreased circulating free fatty acids level J:153477
decreased circulating glucose level J:153477
decreased circulating triglyceride level J:153477
increased circulating leptin level J:153477
Adip1SM/J/?
Capn10tm1Chev/Capn10+

((B6.129-Capn10tm1Chev x SM/J)F1)
decreased circulating cholesterol level J:153477
decreased circulating free fatty acids level J:153477
decreased circulating glucose level J:153477
decreased circulating triglyceride level J:153477
Adipoqtm1Chan/Adipoq+
(B6.129-Adipoqtm1Chan)
decreased circulating adiponectin level J:122020
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
decreased circulating adiponectin level J:147458
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
decreased circulating adiponectin level J:147458
Adipoqtm1Chan/Adipoqtm1Chan
(B6.129-Adipoqtm1Chan)
abnormal nitric oxide homeostasis J:122020
decreased circulating adiponectin level J:122020
decreased fatty acid beta-oxidation J:79122
homeostasis/metabolism phenotype J:79122
Adipoqtm1Chan/Adipoqtm1Chan
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
albuminuria J:136297
Adipoqtm1Chan/Adipoqtm1Chan
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lipid homeostasis J:138678
Adipoqtm1Far/Adipoqtm1Far
(involves: C57BL/6J)
impaired glucose tolerance J:111346
Adipoqtm1Far/Adipoqtm1Far
(involves: 129S4/SvJae * C57BL/6J)
impaired glucose tolerance J:111346
increased circulating glucose level J:111346
increased liver triglyceride level J:111346
Adipoqtm1Far/Adipoqtm1Far
Dgat1tm1Far/Dgat1tm1Far

(involves: 129S4/SvJae * C57BL/6J)
abnormal glucose tolerance J:111346
decreased circulating glucose level J:111346
decreased circulating leptin level J:111346
decreased liver cholesterol level J:111346
decreased liver triglyceride level J:111346
increased oxygen consumption J:111346
Adipoqtm1Ish/Adipoq+
Bglap/Bglap2tm1Kry/Bglap+

(involves: 129S7/SvEvBrd)
decreased circulating adiponectin level J:126780
insulin resistance J:126780
Adipoqtm1Ish/Adipoq+
Bglap/Bglap2tm1Kry/Bglap2+

(involves: 129S7/SvEvBrd)
decreased circulating adiponectin level J:126780
insulin resistance J:126780
Adipoqtm1Ish/Adipoqtm1Ish
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal energy homeostasis J:199264
abnormal gas homeostasis J:199264
abnormal glucose homeostasis J:199264
abnormal hormone level J:199264
abnormal lipid level J:77479
abnormal urine homeostasis J:199264
abnormal vascular wound healing J:79350
decreased insulin secretion J:199264
homeostasis/metabolism phenotype J:199264
hyperglycemia J:77479, J:103106
impaired glucose tolerance J:199264
increased adiponectin level J:199264
increased carbon dioxide production J:199264
increased circulating adiponectin level J:199264
increased circulating free fatty acids level J:77479
increased circulating glucose level J:106599
increased circulating insulin level J:77479
increased circulating osteocalcin level J:199264
increased energy expenditure J:199264
increased noradrenaline level J:199264
increased oxygen consumption J:199264
increased susceptibility to diet-induced obesity J:103106
increased urine adrenaline level J:199264
insulin resistance J:77479
pulmonary edema J:106599
Adipoqtm1Ish/Adipoqtm1Ish
Dbhtm1Rpa/Dbh+

(involves: 129S7/SvEvBrd * C57BL/6J)
homeostasis/metabolism phenotype J:199264
Adipoqtm1Ish/Adipoqtm1Ish
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Tg(Col1a1-cre)1Kry/0

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J * FVB/N)
homeostasis/metabolism phenotype J:199264
Adipoqtm1Ish/Adipoqtm1Ish
Lepob/Lepob

(involves: 129S7/SvEvBrd * C57BL/6J)
decreased carbon dioxide production J:199264
decreased energy expenditure J:199264
decreased oxygen consumption J:199264
impaired glucose tolerance J:199264
increased circulating glucose level J:199264
increased urine adrenaline level J:199264
Adipoqtm1Pesch/Adipoqtm1Pesch
(involves: 129S7/SvEvBrd)
abnormal gluconeogenesis J:107486
impaired glucose tolerance J:107486
Adipoqtm1Pesch/Adipoqtm1Pesch
(B6.129S7-Adipoqtm1Pesch)
decreased susceptibility to induced hypothermia J:210480
increased core body temperature J:210480
increased energy expenditure J:210480
increased oxygen consumption J:210480
Adipoqtm1Pesch/Adipoqtm1Pesch
Lepob/Lepob

(involves: 129S7/SvEvBrd * C57BL/6J)
impaired glucose tolerance J:107486
Adipoqtm1Tka/Adipoq+
(involves: 129S4/SvJae * C57BL/6)
impaired glucose tolerance J:77876
insulin resistance J:77876
Adipoqtm1Tka/Adipoqtm1Tka
(involves: 129S4/SvJae * C57BL/6)
abnormal vascular wound healing J:77876
impaired glucose tolerance J:77876
increased circulating triglyceride level J:77876
insulin resistance J:77876
Adipor1tm1.1Kry/Adipor1tm1.1Kry
Adipor2tm1.1Kry/Adipor2tm1.1Kry
Tg(Col1a1-cre)1Kry/0

(involves: 129 * C57BL/6J * FVB)
homeostasis/metabolism phenotype J:199264
Adipor1tm1.1Kry/Adipor1tm1.1Kry
Tg(Col1a1-cre)1Kry/0

(involves: 129 * C57BL/6J * FVB)
homeostasis/metabolism phenotype J:199264
Adipor1tm1b(EUCOMM)Hmgu/Adipor1tm1b(EUCOMM)Hmgu
(C57BL/6N-Adipor1tm1b(EUCOMM)Hmgu/H)
decreased circulating calcium level J:211773
increased blood urea nitrogen level J:211773
increased circulating alanine transaminase level J:211773
increased circulating cholesterol level J:211773
increased circulating HDL cholesterol level J:211773
increased circulating phosphate level J:211773
Adipor1tm1b(EUCOMM)Hmgu/Adipor1tm1b(EUCOMM)Hmgu
(C57BL/6N-Adipor1tm1b(EUCOMM)Hmgu/Orl)
decreased circulating alkaline phosphatase level J:211773
decreased circulating calcium level J:211773
increased circulating phosphate level J:211773
increased circulating triglyceride level J:211773
Adipor1tm1Dgen/Adipor1tm1Dgen
(B6.129P2-Adipor1tm1Dgen/Mmnc)
abnormal lipid homeostasis J:122027
decreased energy expenditure J:122027
impaired glucose tolerance J:122027
increased circulating cholesterol level J:122027
increased circulating leptin level J:122027
increased liver triglyceride level J:122027
Adipor1tm1Dgen/Adipor1tm1Dgen
(involves: 129P2/OlaHsd)
abnormal adaptive thermogenesis J:210480
decreased adiponectin level J:210480
decreased circulating adiponectin level J:210480
impaired adaptive thermogenesis J:210480
Adipor1tm1Tka/Adipor1tm1Tka
(involves: 129S4/SvJae * C57BL/6)
abnormal enzyme/coenzyme activity J:117919
abnormal glucose homeostasis J:117919
hyperglycemia J:117919
impaired glucose tolerance J:117919
increased circulating glucose level J:117919
increased circulating insulin level J:117919
insulin resistance J:117919
Adipor1tm1Tka/Adipor1tm1Tka
Adipor2tm1Tka/Adipor2tm1Tka

(involves: 129S4/SvJae * C57BL/6)
abnormal circulating glucose level J:117919
abnormal enzyme/coenzyme activity J:117919
abnormal gluconeogenesis J:117919
abnormal glucose homeostasis J:117919
hyperglycemia J:117919
impaired glucose tolerance J:117919
increased liver triglyceride level J:117919
insulin resistance J:117919
Adipor1tm2Tka/Adipor1tm2Tka
Tg(Ckmm-cre)5Khn/0

(B6.Cg-Adipor1tm2Tka Tg(Ckmm-cre)5Khn)
abnormal glucose homeostasis J:159462
decreased oxygen consumption J:159462
impaired exercise endurance J:159462
increased circulating glucose level J:159462
increased circulating insulin level J:159462
increased skeletal muscle triglyceride level J:159462
insulin resistance J:159462
Adipor2tm1.1Kry/Adipor2tm1.1Kry
Tg(Col1a1-cre)1Kry/0

(involves: 129 * C57BL/6J * FVB)
homeostasis/metabolism phenotype J:199264
Adipor2tm1Dgen/Adipor2tm1Dgen
(B6.129P2-Adipor2tm1Dgen)
abnormal hormone level J:122027
abnormal lipid homeostasis J:122027
decreased circulating cholesterol level J:122027
decreased circulating HDL cholesterol level J:122027
decreased circulating insulin level J:122027
decreased liver triglyceride level J:122027
decreased susceptibility to diet-induced obesity J:122027
improved glucose tolerance J:122027
increased circulating adiponectin level J:122027
increased energy expenditure J:122027
Adipor2tm1Dgen/Adipor2tm1Dgen
(B6.129P2-Adipor2tm1Dgen/J)
abnormal adaptive thermogenesis J:210480
homeostasis/metabolism phenotype J:210480
impaired adaptive thermogenesis J:210480
Adipor2tm1Tka/Adipor2tm1Tka
(involves: 129S4/SvJae * C57BL/6)
abnormal glucose homeostasis J:117919
hyperglycemia J:117919
impaired glucose tolerance J:117919
increased circulating insulin level J:117919
insulin resistance J:117919
Adipor2tm2Dgen/Adipor2tm2Dgen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal glucose homeostasis J:129554
decreased circulating cholesterol level J:129554
decreased circulating HDL cholesterol level J:129554
decreased circulating insulin level J:129554
decreased circulating LDL cholesterol level J:129554
decreased circulating triglyceride level J:129554
decreased circulating VLDL cholesterol level J:129554
decreased susceptibility to diet-induced obesity J:129554
increased circulating adiponectin level J:129554
increased circulating glucose level J:129554
Adktm1Bois/Adktm1Bois
(involves: 129P3/JEmsJ * C57BL/6)
abnormal body temperature homeostasis J:81518
abnormal homeostasis J:81518
abnormal nucleotide metabolism J:81518
Adm2em1Zhan/Adm2em1Zhan
(Not Specified)
abnormal susceptibility to injury induced morbidity/mortality J:266495
increased susceptibility to injury J:266495
Admtm1Hku/Admtm1Hku
(involves: 129S6/SvEvTac * C57BL/6)
hydrops fetalis J:89608
pericardial effusion J:89608
Admtm1Unc/Admtm1Unc
(involves: 129S6/SvEvTac)
hydrops fetalis J:67044, J:106927
Admtm1Unc/Admtm1Unc
(129S6/SvEvTac-Admtm1Unc)
edema J:130930
lymphedema J:130930
Adnp2em3(IMPC)Tcp/Adnp2em3(IMPC)Tcp
(C57BL/6NCrl-Adnp2em3(IMPC)Tcp/Tcp)
decreased circulating total protein level J:211773
Adora1tm1Bbf/Adora1tm1Bbf
(involves: 129P2/OlaHsd * C57BL)
abnormal body temperature homeostasis J:70664
Adora1tm1Bbf/Adora1tm1Bbf
(involves: 129P2/OlaHsd * C57BL/6)
homeostasis/metabolism phenotype J:99612
Adora1tm1Jgsc/Adora1tm1Jgsc
(involves: 129S1/Sv * 129X1/SvJ)
abnormal response/metabolism to endogenous compounds J:92598
Adora1tm1Jgsc/Adora1tm1Jgsc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased circulating creatinine level J:127544
increased susceptibility to kidney reperfusion injury J:127544
Adora1tm1Jgsc/Adora1tm1Jgsc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
homeostasis/metabolism phenotype J:71091
Adora2aem1(IMPC)H/Adora2aem1(IMPC)H
(C57BL/6N-Adora2aem1(IMPC)H/H)
increased circulating alanine transaminase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating glucose level J:211773
increased fasting circulating glucose level J:211773
Adora2atm1Jfc/Adora2atm1Jfc
(involves: 129S4/SvJae * C57BL/6)
decreased cerebral infarct size J:73594
decreased susceptibility to ischemic brain injury J:73594
Adora2atm1Jfc/Adora2atm1Jfc
(involves: 129S4/SvJae * 129S6/SvEvTac)
decreased cerebral infarct size J:73594
decreased physiological sensitivity to xenobiotic J:106215
decreased susceptibility to ischemic brain injury J:73594
Adora2atm1Map/Adora2atm1Map
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
increased platelet aggregation J:42276
Adora2btm1.1(KOMP)Vlcg/Adora2b+
(B6N(Cg)-Adora2btm1.1(KOMP)Vlcg/J)
increased fasting circulating glucose level J:211773
Adora2btm1.1(KOMP)Vlcg/Adora2btm1.1(KOMP)Vlcg
(B6N(Cg)-Adora2btm1.1(KOMP)Vlcg/J)
decreased circulating glucose level J:211773
increased circulating alkaline phosphatase level J:211773
Adora2btm1.1Msit/Adora2btm1.1Msit
(either: (involves: C57BL/6) or (involves: C57BL/6 * CD-1 * ICR))
decreased susceptibility to injury J:169155
Adora2btm1.1Msit/Adora2btm1.1Msit
(involves: BALB/cJ)
increased susceptibility to injury J:203572
Adora2btm1Dgen/Adora2btm1Dgen
(involves: 129P2/OlaHsd)
abnormal response to cardiac infarction J:131444
decreased susceptibility to injury J:234143
Adora2btm1Dgen/Adora2btm1Dgen
(B6.129P2-Adora2btm1Dgen)
abnormal response to injury J:131314
Adora2btm1Kra/Adora2btm1Kra
(involves: 129 * C57BL/6J)
abnormal cytokine level J:111715
abnormal interleukin level J:111715
abnormal tumor necrosis factor level J:111715
increased circulating interleukin-6 level J:111715
Adora2btm1Msit/Adora2btm1Msit
Lyz2tm1(cre)Ifo/Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to injury J:169155
Adora2btm1Msit/Adora2btm1Msit
Tg(Cdh5-cre)7Mlia/0

(involves: FVB/N)
homeostasis/metabolism phenotype J:203572
Adora2btm1Msit/Adora2btm1Msit
Tg(Sftpc-cre)1Blh/0

(involves: C57BL/6 * DBA/2)
increased susceptibility to injury J:203572
Adora2btm1Till/Adora2btm1Till
(B6.129P2-Adora2btm1Till)
decreased physiological sensitivity to xenobiotic J:125297
homeostasis/metabolism phenotype J:125297
impaired adaptive thermogenesis J:125297
Adora3tm1Jbsn/Adora3tm1Jbsn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal response/metabolism to endogenous compounds J:77069, J:61026
decreased myocardial infarct size J:103737
Adora3tm1Jbsn/Adora3tm1Jbsn
(B6.129P2-Adora3tm1Jbsn)
abnormal response/metabolism to endogenous compounds J:123463
decreased circulating creatinine level J:82054
decreased susceptibility to kidney reperfusion injury J:82054
Adprhl1em1(IMPC)H/Adprhl1em1(IMPC)H
(C57BL/6NTac-Adprhl1em1(IMPC)H/H)
increased circulating cholesterol level J:211773
Adprmtm1b(EUCOMM)Hmgu/Adprmtm1b(EUCOMM)Hmgu
(C57BL/6N-Adprmtm1b(EUCOMM)Hmgu/Ieg)
decreased respiratory quotient J:211773
Adprsem1(IMPC)Wtsi/Adprsem1(IMPC)Wtsi
(C57BL/6N-Adprsem1(IMPC)Wtsi/WtsiIeg)
increased circulating alkaline phosphatase level J:211773
Adprstm1.2Jlms/Adprstm1.2Jlms
(involves: 129 * C57BL/6J * FVB/N * SJL)
abnormal susceptibility to injury induced morbidity/mortality J:291285
increased susceptibility to ischemic brain injury J:291285
Adra1atm1Pcs/Adra1atm1Pcs
Adra1btm1Cta/Adra1btm1Cta

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
impaired exercise endurance J:83876
increased response of heart to induced stress J:83876
Adra1btm1Cta/Adra1btm1Cta
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal glucose homeostasis J:87718
decreased circulating free fatty acids level J:87718
decreased skeletal muscle glycogen level J:87718
hyperglycemia J:87718
impaired glucose tolerance J:87718
increased circulating insulin level J:87718
increased circulating leptin level J:87718
increased liver glycogen level J:87718
increased susceptibility to diet-induced obesity J:87718
insulin resistance J:87718
Adra1btm1Cta/Adra1btm1Cta
(involves: 129 * C57BL/6J)
decreased circulating testosterone level J:125763
increased circulating luteinizing hormone level J:125763
Adra2am1Btlr/Adra2am1Btlr
(C57BL/6J-Adra2am1Btlr)
decreased circulating glucose level J:267700
increased circulating insulin level J:267700
Adra2am2Btlr/Adra2am2Btlr
(C57BL/6J-Adra2am2Btlr)
decreased circulating glucose level J:267701
Adra2atm1.1(KOMP)Vlcg/Adra2atm1.1(KOMP)Vlcg
(C57BL/6N-Adra2atm1.1(KOMP)Vlcg/Ucd)
decreased fasting circulating glucose level J:211773
improved glucose tolerance J:211773
Adra2atm1Bkk/Adra2atm1Bkk
(involves: 129S1/Sv * 129X1/SvJ)
abnormal glucose homeostasis J:130781
hypoglycemia J:130781
Adra2btm1Gsb/Adra2btm1Gsb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
homeostasis/metabolism phenotype J:89316
Adra2btm1Gsb/Adra2btm1Gsb
(B6.129-Adra2btm1Gsb)
cyanosis J:166788
Adra2ctm1Gsb/Adra2ctm1Gsb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2J)
homeostasis/metabolism phenotype J:38466, J:89316
Adrb1tm1Bkk/Adrb1tm1Bkk
(either: (involves: 129/Sv) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2))
abnormal physiological response to xenobiotic J:34659
Adrb1tm1Bkk/Adrb1tm1Bkk
Adrb2tm1Bkk/Adrb2tm1Bkk

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)
abnormal physiological response to xenobiotic J:55553
abnormal response/metabolism to endogenous compounds J:55553
decreased oxygen consumption J:55553
Adrb1tm1Bkk/Adrb1tm1Bkk
Adrb2tm1Bkk/Adrb2tm1Bkk
Adrb3tm1Lowl/Adrb3tm1Lowl

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)
decreased oxygen consumption J:79309
impaired adaptive thermogenesis J:79309
increased circulating leptin level J:79309
Adrb2tm1Bkk/Adrb2tm1Bkk
(FVB.129-Adrb2tm1Bkk)
decreased respiratory quotient J:55552
enhanced exercise endurance J:55552
homeostasis/metabolism phenotype J:55552
Adrb2tm1Kry/Adrb2+
Lepob/Lep+
Tg(Col1a1-cre)1Kry/0

(involves: C57BL/6 * C57BL/10J * FVB)
decreased circulating glucose level J:145998
increased circulating insulin level J:145998
Adrb2tm1Kry/Adrb2tm1Kry
Tg(Col1a1-cre)1Kry/0

(involves: FVB)
abnormal insulin secretion J:145998
decreased circulating glucose level J:145998
increased circulating insulin level J:145998
Adrb3tm1Jpg/Adrb3tm1Jpg
(involves: 129S4/SvJae * C57BL/6J)
homeostasis/metabolism phenotype J:42702
Adrb3tm1Lowl/Adrb3tm1Lowl
(FVB/N-Adrb3tm1Lowl)
abnormal physiological response to xenobiotic J:30060
Adrm1Gt(OST128063)Lex/Adrm1Gt(OST128063)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
homeostasis/metabolism phenotype J:166694
increased circulating follicle stimulating hormone level J:166694
increased circulating growth hormone level J:166694
Ads4NZB/Ads4NZB
(involves: NZB * NZW)
increased urine protein level J:11074
Adslem1Svap/Adslem1Svap
(C57BL/6NCrl-Adslem1Svap)
abnormal amino acid metabolism J:307180
Adsstm1b(EUCOMM)Wtsi/Adss+
(C57BL/6N-Adsstm1b(EUCOMM)Wtsi/Bay)
decreased blood urea nitrogen level J:211773
decreased circulating creatinine level J:211773
increased circulating HDL cholesterol level J:211773
Adtrpem1Sagh/Adtrpem1Sagh
(involves: C57BL/6)
abnormal lipid metabolism J:289837
increased fatty acids level J:289837
Adtrpem1Sagh/Adtrpem1Sagh
Aig1em1Sagh/Aig1em1Sagh

(involves: C57BL/6)
abnormal lipid metabolism J:289837
homeostasis/metabolism phenotype J:289837
increased fatty acids level J:289837
Adtrptm1.1Clu/Adtrptm1.1Clu
(involves: 129S4/SvJaeSor * C57BL/6)
increased bleeding time J:295059
skin edema J:295059
Aebp1tm1Hsro/Aebp1tm1Hsro
(involves: 129S4/SvJae * C57BL/6J)
decreased circulating cholesterol level J:125333
decreased circulating triglyceride level J:125333
decreased susceptibility to diet-induced obesity J:125333
Aebp1tm1Mdl/Aebp1tm1Mdl
(involves: 129S2/SvPas * C57BL/6)
impaired wound healing J:70416
Aec1NOD/Uf/Aec1NOD/Uf
Aec2NOD/Uf/Aec2NOD/Uf

(B6.NOD-Aec2NOD/Uf Aec1NOD/Uf)
abnormal enzyme/coenzyme activity J:128900
decreased salivation J:128900, J:129282, J:129916
Afap1l2tm1.1Mliu/Afap1l2tm1.1Mliu
(B6.129P2(Cg)-Afap1l2tm1.1Mliu)
abnormal response to injury J:223478
homeostasis/metabolism phenotype J:223478
Afap1l2tm1b(KOMP)Wtsi/Afap1l2tm1b(KOMP)Wtsi
(C57BL/6N-Afap1l2tm1b(KOMP)Wtsi/Ucd)
improved glucose tolerance J:211773
increased circulating alkaline phosphatase level J:211773
Aff3tm1a(EUCOMM)Wtsi/Aff3tm1a(EUCOMM)Wtsi
(C57BL/6N-Aff3tm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating fructosamine level J:211773
decreased circulating serum albumin level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating chloride level J:211773
Aff4em1(IMPC)Mbp/Aff4em1(IMPC)Mbp
(C57BL/6N-Aff4em1(IMPC)Mbp/MbpMmucd)
edema J:211773
Afmidtm1a(EUCOMM)Wtsi/Afmidtm1a(EUCOMM)Wtsi
(C57BL/6N-Afmidtm1a(EUCOMM)Wtsi/H)
hyperglycemia J:226537
Afmidtm1b(EUCOMM)Wtsi/Afmid+
(C57BL/6N-Afmidtm1b(EUCOMM)Wtsi/H)
impaired glucose tolerance J:226537
Afmidtm1b(EUCOMM)Wtsi/Afmidtm1b(EUCOMM)Wtsi
(C57BL/6N-Afmidtm1b(EUCOMM)Wtsi/H)
abnormal urine homeostasis J:226537
decreased insulin secretion J:226537
impaired glucose tolerance J:226537
increased circulating fructosamine level J:226537
increased circulating glucose level J:211773, J:226537
Afptm1(Cebpa)Ndw/Afp+
(involves: 129S7/SvEvBrd)
decreased incidence of tumors by chemical induction J:103404
increased liver glycogen level J:103404
Afptm1Ibmm/Afptm1Ibmm
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1))
decreased circulating progesterone level J:79500
increased circulating follicle stimulating hormone level J:79500
increased circulating luteinizing hormone level J:79500
Afptm2Ibmm/Afptm2Ibmm
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1))
decreased circulating progesterone level J:79500
increased circulating follicle stimulating hormone level J:79500
increased circulating luteinizing hormone level J:79500
Afteq1ILS/Afteq1ILS
Afteq2ISS/Afteq2ISS

(involves: ILS * ISS)
abnormal ethanol metabolism J:122921
Afteq1ISS/Afteq1ISS
(involves: ILS * ISS)
abnormal ethanol metabolism J:122921
Afteq2ILS/Afteq2ILS
(involves: ILS * ISS)
abnormal ethanol metabolism J:122921
Afteq2ISS/Afteq2ISS
(involves: ILS * ISS)
abnormal ethanol metabolism J:122921
Agatm1Pltn/Agatm1Pltn
(involves: 129S4/SvJae * C57BL/6)
aspartylglucosaminuria J:45587
Agatm1Vk/Agatm1Vk
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
abnormal urine homeostasis J:37022, J:60272
aspartylglucosaminuria J:37022
colorless urine J:91114
Agap1tm1a(EUCOMM)Wtsi/Agap1tm1a(EUCOMM)Wtsi
(C57BL/6N-Agap1tm1a(EUCOMM)Wtsi/Wtsi)
increased circulating alkaline phosphatase level J:211773
increased circulating potassium level J:211773
Agap2tm1.1Kye/Agap2tm1.1Kye
(Not Specified)
abnormal gluconeogenesis J:174775
hyperglycemia J:174775
increased insulin sensitivity J:174775
insulin resistance J:174775
Agap2tm1Kye/Agap2tm1Kye
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: C57BL/6 * DBA/2)
abnormal gluconeogenesis J:174775
decreased circulating triglyceride level J:174775
decreased liver cholesterol level J:174775
decreased liver free fatty acids level J:174775
decreased liver triglyceride level J:174775
homeostasis/metabolism phenotype J:174775
hyperglycemia J:174775
impaired glucose tolerance J:174775
increased circulating insulin level J:174775
insulin resistance J:174775
Agbl4em1(IMPC)Mbp/Agbl4em1(IMPC)Mbp
(C57BL/6NCrl-Agbl4em1(IMPC)Mbp/Mmucd)
increased circulating bilirubin level J:211773
Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu/Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu
(involves: FVB/N)
abnormal hemostasis J:233744
abnormal platelet physiology J:233744
decreased platelet aggregation J:233744
increased bleeding time J:233744
Agertm1.1Arnd/Agertm1.1Arnd
(involves: 129P2/OlaHsd * C57BL/6)
abnormal vascular wound healing J:82620
increased circulating glucose level J:82491
Agertm1.1Hyam/Ager+
Tg(Ins2-Nos2)40Okam/0

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA/2)
hyperglycemia J:116040
Agertm1.1Hyam/Agertm1.1Hyam
(involves: 129P2/OlaHsd * C57BL/6J * CD-1)
abnormal blood homeostasis J:116507
increased circulating glucose level J:116507
Agertm1.1Hyam/Agertm1.1Hyam
Tg(Ins2-Nos2)40Okam/0

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA/2)
albuminuria J:116040
decreased circulating creatinine level J:116040
hyperglycemia J:116040
Agltm1a(EUCOMM)Wtsi/Agltm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
hypoglycemia J:212003
increased cardiac muscle glycogen level J:212003
increased circulating alanine transaminase level J:212003
increased circulating alkaline phosphatase level J:212003
increased circulating aspartate transaminase level J:212003
increased circulating creatine kinase level J:212003
increased liver glycogen level J:212003
increased skeletal muscle glycogen level J:212003
Agltm1b(EUCOMM)Wtsi/Agltm1b(EUCOMM)Wtsi
(C57BL/6N-Agltm1b(EUCOMM)Wtsi/H)
decreased circulating glucose level J:211773
impaired glucose tolerance J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating amylase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating bilirubin level J:211773
increased circulating cholesterol level J:211773
increased circulating creatine kinase level J:211773
increased circulating iron level J:211773
increased fasting circulating glucose level J:211773
Agltm1Geno/Agltm1Geno
(C57BL/6J-Agltm1Geno)
decreased circulating glucose level J:218471
decreased fasting circulating glucose level J:218471
impaired exercise endurance J:218471
increased brain glycogen level J:218471
increased cardiac muscle glycogen level J:218471
increased circulating alanine transaminase level J:218471
increased circulating alkaline phosphatase level J:218471
increased circulating aspartate transaminase level J:218471
increased circulating creatine kinase level J:218471
increased glycogen level J:218471
increased liver glycogen level J:218471
increased skeletal muscle glycogen level J:218471
Agmotm2a(EUCOMM)Wtsi/Agmotm2a(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal enzyme/coenzyme activity J:308367
decreased circulating cholesterol level J:308367
homeostasis/metabolism phenotype J:308367
Agmotm2d(EUCOMM)Wtsi/Agmotm2d(EUCOMM)Wtsi
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
abnormal enzyme/coenzyme activity J:308367
Ago2tm1.1Tara/Ago2tm1.1Tara
Lepob/Lepob
Tg(Ins2-cre)23Herr/0

(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
decreased circulating glucose level J:210552
decreased circulating insulin level J:210552
improved glucose tolerance J:210552
increased circulating insulin level J:210552
Ago2tm1.1Tara/Ago2tm1.1Tara
Tg(Ins2-cre)23Herr/0

(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
homeostasis/metabolism phenotype J:210552
improved glucose tolerance J:210552
Ago2tm1Ghan/Ago2tm1Ghan
(involves: C57BL/6)
pericardial edema J:93081
Agpat1tm1.1(KOMP)Vlcg/Agpat1+
(B6N(Cg)-Agpat1tm1.1(KOMP)Vlcg/J)
decreased circulating calcium level J:211773
decreased circulating chloride level J:211773
decreased circulating glucose level J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating potassium level J:211773
increased urine glucose level J:211773
increased urine microalbumin level J:211773
Agpat1tm1Garg/Agpat1tm1Garg
(involves: 129S6/SvEvTac * C57BL/6)
abnormal enzyme/coenzyme activity J:250301
decreased circulating glucose level J:250301
decreased circulating insulin-like growth factor I level J:250301
decreased circulating leptin level J:250301
homeostasis/metabolism phenotype J:250301
hypoglycemia J:250301
impaired gluconeogenesis J:250301
increased circulating follicle stimulating hormone level J:250301
increased circulating luteinizing hormone level J:250301
Agpat2Gt(OST438470)Lex/Agpat2Gt(OST438470)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
hyperglycemia J:186035
increased circulating glucose level J:186035
increased circulating insulin level J:186035
Agpat2tm1Garg/Agpat2tm1Garg
(involves: 129S6/SvEvTac)
abnormal fatty acids level J:146649
abnormal gas homeostasis J:146649
abnormal glucose homeostasis J:146649
abnormal lipid homeostasis J:146649
abnormal phospholipid level J:146649
decreased body temperature J:146649
decreased circulating free fatty acids level J:146649
decreased circulating leptin level J:146649
decreased respiratory quotient J:146649
homeostasis/metabolism phenotype J:231617
hyperglycemia J:146649
improved glucose tolerance J:231617
increased carbon dioxide production J:146649
increased circulating cholesterol level J:231617
increased circulating glucose level J:231617
increased circulating insulin level J:231617, J:146649
increased circulating triglyceride level J:146649
increased liver triglyceride level J:231617, J:146649
increased oxygen consumption J:146649
insulin resistance J:231617, J:146649
Agpat2tm1Garg/Agpat2tm1Garg
Mogat1tm1Far/Mogat1tm1Far

(involves: 129S4/SvJae * 129S6/SvEvTac)
homeostasis/metabolism phenotype J:231617
improved glucose tolerance J:231617
increased circulating glucose level J:231617
increased circulating insulin level J:231617
increased liver triglyceride level J:231617
insulin resistance J:231617
Agpat3tm1a(EUCOMM)Wtsi/Agpat3+
(B6JTyr;B6N-Agpat3tm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating alanine transaminase level J:175295
decreased circulating aspartate transaminase level J:175295
decreased lactate dehydrogenase level J:175295
Agpat3tm1a(EUCOMM)Wtsi/Agpat3tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal phospholipid level J:245638
Agpat3tm1a(EUCOMM)Wtsi/Agpat3tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
abnormal phospholipid level J:246569
Agpat4tm1b(KOMP)Wtsi/Agpat4tm1b(KOMP)Wtsi
(C57BL/6N-Agpat4tm1b(KOMP)Wtsi/H)
increased fasting circulating glucose level J:211773
Agpat4tm1Lex/Agpat4tm1Lex
(B6;129S5-Agpat4tm1Lex/Mmucd)
abnormal phospholipid level J:231388
Agpsbs2/Agpsbs2
(STOCK Agpsbs2/J)
abnormal lipid level J:171265
Agr2tm1.1Lex/Agr2tm1.1Lex
(involves: 129S5/SvEvBrd * BALB/cJ * C57BL/6)
decreased circulating serum albumin level J:195573
Agrntm1Rwb/Agrntm1Rwb
Tg(APPswe,PSEN1dE9)85Dbo/?
Tg(Tek-cre)1Ywa/?

(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL)
amyloid beta deposits J:220073
Agrptm1(cre)Lowl/Agrp+
Slc32a1tm1Lowl/Slc32a1tm1Lowl

(involves: 129S6/SvEvTac * C57BL/6)
decreased respiratory quotient J:140858
decreased susceptibility to diet-induced obesity J:140858
increased oxygen consumption J:140858
Agrptm1Dgen/Agrptm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating ketone body level J:199803
decreased circulating VLDL triglyceride level J:199803
decreased liver triglyceride level J:199803
homeostasis/metabolism phenotype J:199803
increased noradrenaline level J:199803
Agrptm1Mws/Agrptm1Mws
(B6.129S1-Agrptm1Mws)
abnormal blood homeostasis J:117539
abnormal energy expenditure J:117539
decreased cholesterol level J:117539
decreased circulating leptin level J:117539
decreased respiratory quotient J:117539
increased circulating thyroxine level J:117539
increased circulating triiodothyronine level J:117539
increased core body temperature J:117539
Agrptm1Sqn/Agrptm1Sqn
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal energy expenditure J:116654
impaired adaptive thermogenesis J:116654
Agrptm2(DTR)Rpa/Agrp+
Lepob/Lepob

(involves: 129S4/SvJaeSor * C57BL/6)
decreased body temperature J:181947
improved glucose tolerance J:181947
Agrptm2(DTR)Rpa/Agrp+
Tph2tm1Mscl/Tph2tm1Mscl

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * C57BL/6NCr)
decreased serotonin level J:182577
Agttm1.1Itl/Agttm1.1Itl
Tg(Fabp4-cre)1Rev/0

(involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)
decreased circulating angiotensinogen level J:178836
homeostasis/metabolism phenotype J:178836
Agttm1Afu/Agt+
(involves: C57BL/6 * CBA * ICR)
abnormal blood homeostasis J:21887
decreased circulating angiotensinogen level J:21887
Agttm1Afu/Agttm1Afu
(involves: C57BL/6 * CBA * ICR)
abnormal blood homeostasis J:73163
abnormal enzyme/coenzyme level J:38494
decreased circulating angiotensinogen level J:21887
increased circulating renin level J:73163, J:36820
Agttm1Afu/Agttm1Afu
(involves: C57BL/6 * CBA)
decreased circulating aldosterone level J:46506
decreased urine aldosterone level J:46506
decreased urine osmolality J:46506
decreased urine potassium level J:46506
decreased urine sodium level J:46506
increased circulating antidiuretic hormone level J:46506
increased urine antidiuretic hormone level J:46506
Agttm1Afu/Agttm1Afu
Tg(Fabp4-Agt)2Mte/0

(involves: C57BL/6 * CBA * DBA/2 * ICR)
decreased circulating angiotensinogen level J:73163
Agttm1Ii/Agttm1Ii
(involves: 129P2/OlaHsd * C57BL/6)
decreased urine osmolality J:140022
increased circulating creatinine level J:140022
Agttm1Unc/Agt+
(involves: 129P2/OlaHsd * C57BL/6J)
decreased circulating angiotensinogen level J:18272, J:24156
increased circulating renin level J:24156
Agttm1Unc/Agttm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
decreased circulating angiotensinogen level J:24156
Agttm1Unc/Agttm2Unc
(involves: 129P2/OlaHsd * C57BL/6J)
decreased circulating angiotensinogen level J:24156
Agttm2Unc/Agt+
(involves: 129P2/OlaHsd * C57BL/6J)
increased circulating angiotensinogen level J:18272, J:24156
Agttm2Unc/Agttm2Unc
(involves: 129P2/OlaHsd * C57BL/6J)
increased circulating angiotensinogen level J:24156
Agtpbp1pcd-3J/Agtpbp1pcd-3J
(BALB/cByJ-Agtpbp1pcd-3J/J)
homeostasis/metabolism phenotype J:233744
Agtr1atm1.1Cof/Agtr1atm1.1Cof
Hprttm1(Pck1-cre)Vhh/Hprt+

(involves: 129 * 129P2/OlaHsd)
abnormal renal water reabsorption J:172240
Agtr1atm1.1Uky/Agtr1atm1.1Uky
Tg(Fabp4-cre)1Rev/0

(involves: C57BL/6 * C57BL/6N * SJL)
homeostasis/metabolism phenotype J:192945
Agtr1atm1Afu/Agtr1a+
(involves: C57BL/6 * CBA * ICR)
homeostasis/metabolism phenotype J:28041
Agtr1atm1Afu/Agtr1atm1Afu
(involves: C57BL/6 * CBA)
decreased susceptibility to injury J:100334
Agtr1atm1Afu/Agtr1atm1Afu
(involves: C57BL/6 * CBA * ICR)
increased circulating renin level J:28041
increased renin activity J:28041
Agtr1atm1Ecl/Agtr1atm1Ecl
(involves: 129S2/SvPas * C57BL/6)
abnormal blood homeostasis J:124206
decreased circulating angiotensin II level J:124206
decreased circulating renin level J:124206
decreased physiological sensitivity to xenobiotic J:124206
decreased urine creatinine level J:124206
decreased urine potassium level J:124206
increased blood urea nitrogen level J:124206
increased urine osmolality J:124206
Agtr1atm1Unc/Agtr1atm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
abnormal physiological response to xenobiotic J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Agtr1btm1Cof/Agtr1btm1Cof

(involves: 129P2/OlaHsd * C57BL/6)
abnormal circulating protein level J:137944
abnormal physiological response to xenobiotic J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Agtr1btm1Cof/Agtr1btm1Cof
Agtr2tm1Tin/Y

(involves: 129P2/OlaHsd * C57BL/6)
abnormal physiological response to xenobiotic J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Agtr1btm1Cof/Agtr1btm1Cof
Agtr2tm1Tin/Agtr2tm1Tin

(involves: 129P2/OlaHsd * C57BL/6)
abnormal physiological response to xenobiotic J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Agtr1btm1Cof/Agtr1btm1Cof
Hprttm1(Ggt1-Agtr1)Cof/Y

(involves: 129P2/OlaHsd)
decreased renin activity J:91837
Agtr1atm1Unc/Agtr1atm1Unc
Agtr2tm1Tin/Y

(involves: 129P2/OlaHsd * C57BL/6)
abnormal circulating protein level J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Agtr2tm1Tin/Agtr2tm1Tin

(involves: 129P2/OlaHsd * C57BL/6)
abnormal circulating protein level J:137944
abnormal response/metabolism to endogenous compounds J:137944
Agtr1atm1Unc/Agtr1atm1Unc
Hprttm1(Ggt1-Agtr1)Cof/Y

(involves: 129P2/OlaHsd)
decreased urine osmolality J:91837
Agtr1atm3Tma/Agtr1atm3Tma
Tg(Nphs1-cre)10Mska/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
homeostasis/metabolism phenotype J:240316
Agtr2tm1a(EUCOMM)Wtsi/Agtr2tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Agtr2tm1a(EUCOMM)Wtsi/Wtsi)
decreased circulating alanine transaminase level J:175295
decreased circulating LDL cholesterol level J:175295
Agtr2tm1Gsb/Y
(FVB.129-Agtr2tm1Gsb)
abnormal response to cardiac infarction J:103066
Agtr2tm1Gsb/Y
(involves: 129S1/Sv * 129X1/SvJ)
increased susceptibility to injury J:100334
Agtr2tm1Gsb/Agtr2tm1Gsb
(involves: 129S1/Sv * 129X1/SvJ)
increased susceptibility to injury J:100334
Agtr2tm1Tin/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal aldosterone level J:102984
abnormal corticosterone level J:102984
abnormal response/metabolism to endogenous compounds J:137944
decreased body temperature J:29457
increased adrenaline level J:102984
increased circulating adrenocorticotropin level J:102984
increased circulating corticosterone level J:102984
increased noradrenaline level J:102984
increased physiological sensitivity to xenobiotic J:146326
Agtr2tm1Tin/Y
(involves: 129P2/OlaHsd)
abnormal circulating insulin level J:105210
abnormal circulating leptin level J:105210
abnormal glucose homeostasis J:105210
abnormal lipid homeostasis J:105210
abnormal respiratory quotient J:105210
abnormal response/metabolism to endogenous compounds J:105210
abnormal skeletal muscle triglyceride level J:105210
abnormal urine homeostasis J:60075
abnormal urine sodium level J:60075
decreased susceptibility to diet-induced obesity J:105210
increased energy expenditure J:105210
increased insulin sensitivity J:105210
increased physiological sensitivity to xenobiotic J:103144
Agtr2tm1Tin/Y
(B6.129P2-Agtr2tm1Tin)
abnormal response to cardiac infarction J:146723
decreased response of heart to induced stress J:63751
Agtr2tm1Tin/Y
(SWR.129P2-Agtr2tm1Tin)
decreased incidence of tumors by chemical induction J:101726
Agtr2tm1Tin/Agtr2tm1Tin
(involves: 129P2/OlaHsd * C57BL/6)
abnormal aldosterone level J:102984
abnormal corticosterone level J:102984
abnormal response/metabolism to endogenous compounds J:137944
increased adrenaline level J:102984
increased circulating adrenocorticotropin level J:102984
increased circulating corticosterone level J:102984
increased noradrenaline level J:102984
increased physiological sensitivity to xenobiotic J:146326
Agtr2tm1Tin/Agtr2tm1Tin
(involves: 129P2/OlaHsd)
abnormal urine homeostasis J:60075
abnormal urine sodium level J:60075
AgtrapGt(XE129)Byg/AgtrapGt(XE129)Byg
(involves: 129P2/OlaHsd)
abnormal blood homeostasis J:185854
decreased urine pH J:185854
homeostasis/metabolism phenotype J:185854
Agtraptm1Tamk/Agtraptm1Tamk
(involves: C57BL/6N)
homeostasis/metabolism phenotype J:263253
increased circulating free fatty acids level J:263253
increased circulating insulin level J:263253
increased circulating serum albumin level J:263253
increased circulating triglyceride level J:263253
insulin resistance J:263253
Agxt2tm1Lex/Agxt2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
increased circulating citrulline level J:207876
Agxttm1Ull/Agxttm1Ull
(B6.129X1-Agxttm1Ull)
crystalluria J:117145
hyperoxaluria J:117145
Agxttm1Ull/Agxttm1Ull
(involves: 129X1/SvJ * C57BL/6)
increased physiological sensitivity to xenobiotic J:181969
Agxttm1Ull/Agxttm1Ull
(involves: 129X1/SvJ * C57BL/6J)
hyperoxaluria J:283585
Agxttm1Ull/Agxttm1Ull
Prodh2em1Jkni/Prodh2em1Jkni

(involves: 129X1/SvJ * C57BL/6J)
abnormal urine homeostasis J:283585
hyperoxaluria J:283585
Ahcyem1Cya/Ahcy+
(C57BL/6N-Ahcyem1Cya/Cya)
abnormal nitric oxide homeostasis J:298071
Ahcyl1tm1a(EUCOMM)Wtsi/Ahcyl1tm1a(EUCOMM)Wtsi
(C57BL/6N-Ahcyl1tm1a(EUCOMM)Wtsi/Wtsi)
increased circulating alkaline phosphatase level J:211773
increased circulating thyroxine level J:211773
Ahi1tm1Jgg/Ahi1+
Lrp6Gt(Ex187)Byg/Lrp6+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
increased circulating creatinine level J:154321
Ahi1tm1Jgg/Ahi1tm1Jgg
Tg(TCF/Lef1-lacZ)34Efu/0

(involves: 129S1/Sv * 129X1/SvJ)
abnormal response to injury J:154321
decreased circulating serum albumin level J:154321
increased circulating creatinine level J:154321
Ahnaktm1b(KOMP)Mbp/Ahnak+
(C57BL/6N-Ahnaktm1b(KOMP)Mbp/H)
improved glucose tolerance J:211773
Ahnaktm1Ysb/Ahnaktm1Ysb
(involves: 129S4/SvJae)
decreased susceptibility to diet-induced obesity J:167048
Ahrb-1/Ahrb-1
(C57BL/6J)
homeostasis/metabolism phenotype J:5387
increased physiological sensitivity to xenobiotic J:113285, J:26440, J:132380
increased sensitivity to xenobiotic induced morbidity/mortality J:113285, J:26440
Ahrb-1/Ahrb-1
(involves: C57BL/6J * DBA/2J)
homeostasis/metabolism phenotype J:5387
Ahrb-1/Ahrb-1
(C58/J)
increased physiological sensitivity to xenobiotic J:26440
increased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrb-1/Ahrb-1
Aiptm2.1Bra/Aiptm2.1Bra
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Aiptm2.1Bra)
abnormal circulating alanine transaminase level J:166864
decreased physiological sensitivity to xenobiotic J:166864
Ahrb-1/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
increased incidence of tumors by chemical induction J:113356
increased physiological sensitivity to xenobiotic J:113356
increased sensitivity to xenobiotic induced morbidity/mortality J:113356
Ahrb-1/Ahrd
(involves: C57BL/6 * DBA/2)
increased sensitivity to xenobiotic induced morbidity/mortality J:113285
Ahrb-2/Ahrb-2
(C3H/He)
increased physiological sensitivity to xenobiotic J:26440
increased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrb-2/Ahrb-2
(A/He)
increased physiological sensitivity to xenobiotic J:26440
increased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrb-3/Ahrb-3
(M. spretus)
homeostasis/metabolism phenotype J:34840, J:22144
Ahrd/Ahrd
(DBA/2J)
decreased physiological sensitivity to xenobiotic J:26440, J:132380
decreased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrd/Ahrd
(AKR)
decreased physiological sensitivity to xenobiotic J:26440
decreased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrd/Ahrd
(DBA/2)
decreased physiological sensitivity to xenobiotic J:26440
decreased sensitivity to xenobiotic induced morbidity/mortality J:26440
Ahrd/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
increased incidence of tumors by chemical induction J:113356
increased physiological sensitivity to xenobiotic J:113356
increased sensitivity to xenobiotic induced morbidity/mortality J:113356
Ahrd/Ahrd
(B6.D2-Ahrd)
decreased physiological sensitivity to xenobiotic J:113285
decreased sensitivity to xenobiotic induced morbidity/mortality J:113285
Ahrtm1(AHR)Mym/Ahrtm1(AHR)Mym
(B6.129P2-Ahrtm1(AHR)Mym)
decreased physiological sensitivity to xenobiotic J:132380
Ahrtm1Bra/Ahrtm1Bra
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased physiological sensitivity to xenobiotic J:83597
Ahrtm1Bra/Ahrtm1Bra
(B6.129-Ahrtm1Bra/J)
abnormal chemokine level J:118646
abnormal cytokine level J:118646
abnormal enzyme/coenzyme activity J:100359
abnormal interleukin level J:118646
abnormal tumor necrosis factor level J:118646
increased physiological sensitivity to xenobiotic J:118646
increased susceptibility to injury J:100359
pulmonary alveolar edema J:100359
pulmonary edema J:100359
Ahrtm1Bra/Ahrtm1Bra
(B6.129-Ahrtm1Bra)
abnormal circulating hormone level J:126176
decreased physiological sensitivity to xenobiotic J:126176
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
abnormal atrial thrombosis J:44690
abnormal thrombosis J:44690
decreased physiological sensitivity to xenobiotic J:25048
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae)
decreased physiological sensitivity to xenobiotic J:36360
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6J)
decreased physiological sensitivity to xenobiotic J:113285
decreased sensitivity to xenobiotic induced morbidity/mortality J:113285
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
abnormal xenobiotic pharmacokinetics J:82937
decreased physiological sensitivity to xenobiotic J:46346
homeostasis/metabolism phenotype J:179919
increased urine uric acid level J:179919
Ahrtm1Yfk/Ahrtm1Yfk
Nfe2l2tm1Mym/Nfe2l2tm1Mym

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J * ICR)
abnormal xenobiotic pharmacokinetics J:82937
Ahrtm2Bra/Ahrtm2Bra
(involves: 129/Sv * C57BL/6)
decreased physiological sensitivity to xenobiotic J:83597
Ahrtm3.1Bra/Ahrtm3.1Bra
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(B6.Cg-Ahrtm3.1Bra Speer6-ps1Tg(Alb-cre)21Mgn)
decreased physiological sensitivity to xenobiotic J:104388
Ahrtm3.1Bra/Ahrtm3.1Bra
Tg(Nes-cre)1Kln/0

(involves: 129/Sv * C57BL/6 * SJL)
decreased susceptibility to ischemic brain injury J:292713
Ahrtm3Bra/Ahrtm3Bra
(involves: 129/Sv * C57BL/6J * DBA/2)
decreased physiological sensitivity to xenobiotic J:94465
Ahrtm4.1Bra/Ahrtm4.1Bra
(involves: 129/Sv * C57BL/6)
decreased physiological sensitivity to xenobiotic J:141978
Ahrrtm1b(KOMP)Wtsi/Ahrr+
(B6N(Cg)-Ahrrtm1b(KOMP)Wtsi/J)
decreased circulating HDL cholesterol level J:211773
Ahrrtm1Yfk/Ahrrtm1Yfk
(involves: 129P2/OlaHsd * C57BL/6)
decreased incidence of tumors by chemical induction J:130214
Ahsgtm1Mbl/Ahsgtm1Mbl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal blood homeostasis J:44632
Ahsgtm1Mbl/Ahsgtm1Mbl
(B6.129-Ahsgtm1Mbl)
decreased circulating free fatty acids level J:78087
decreased circulating insulin level J:78087
decreased circulating triglyceride level J:78087
decreased susceptibility to diet-induced obesity J:78087
improved glucose tolerance J:78087
increased insulin sensitivity J:78087
Aidatm1.1Scli/Aidatm1.1Scli
(involves: C57BL/6 * FVB/N)
abnormal lipid homeostasis J:262001
homeostasis/metabolism phenotype J:262001
hyperglycemia J:262001
increased circulating insulin level J:262001
increased circulating triglyceride level J:262001
increased liver glycogen level J:262001
increased respiratory quotient J:262001
increased susceptibility to diet-induced obesity J:262001
increased triglyceride level J:262001
insulin resistance J:262001
Aif1tm1.1(KOMP)Wtsi/Aif1tm1.1(KOMP)Wtsi
(C57BL/6N-Aif1tm1.1(KOMP)Wtsi/Ieg)
decreased blood urea nitrogen level J:211773
Aifm1Hq/Y
(B6CBACa Aw-J/A-Aifm1Hq/J)
abnormal response to cardiac infarction J:110278
decreased susceptibility to neuronal excitotoxicity J:98103
increased catalase activity J:78983, J:144096
increased myocardial infarct size J:110278
increased superoxide dismutase level J:144096
Aifm1Hq/Aifm1Hq
(B6CBACa Aw-J/A-Aifm1Hq/J)
abnormal response to cardiac infarction J:110278
decreased susceptibility to neuronal excitotoxicity J:98103
increased catalase activity J:78983, J:144096
increased myocardial infarct size J:110278
increased superoxide dismutase level J:144096
Aifm1tm2Pngr/Y
Foxg1tm1(cre)Skm/Foxg1+

(involves: 129P2/OlaHsd)
abnormal enzyme/coenzyme level J:112874
Aifm1tm2Pngr/Y
Tg(Ckmm-cre)5Khn/0

(involves: 129P2/OlaHsd * FVB)
abnormal glucose homeostasis J:113016
abnormal hormone level J:113016
decreased catalase activity J:113016
increased circulating lactate level J:113016
Aifm3em1(IMPC)Rbrc/Aifm3em1(IMPC)Rbrc
(Not Specified)
abnormal cholesterol homeostasis J:211773
abnormal circulating LDL cholesterol level J:211773
increased circulating aspartate transaminase level J:211773
increased fasting circulating glucose level J:211773
Aig1em1Sagh/Aig1em1Sagh
(involves: C57BL/6)
abnormal lipid metabolism J:289837
homeostasis/metabolism phenotype J:289837
Aim2em1(IMPC)Ccpcz/Aim2em1(IMPC)Ccpcz
(C57BL/6N-Aim2em1(IMPC)Ccpcz/Ccpcz)
increased circulating serum albumin level J:211773
increased circulating total protein level J:211773
Aim2Gt(CSG445)Byg/Aim2Gt(CSG445)Byg
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-18 level J:158969
Aim2tm1.2Arte/Aim2tm1.2Arte
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt

(involves: 129 * BALB/c * C57BL/6 * C57BL/6J)
increased circulating interleukin-10 level J:238323
increased circulating tumor necrosis factor level J:238323
Aim2tm1Ktak/Aim2tm1Ktak
(involves: 129S4/SvJae * C57BL/6)
decreased circulating interleukin-18 level J:188013
Aimp1Gt(OST58507)Lex/Aimp1Gt(OST58507)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
delayed wound healing J:95974
Aiptm1Bra/Aiptm1Bra
(involves: 129S4/SvJaeSor * C57BL/6)
pericardial edema J:141575
Airetm1.1(NCOM)Mfgc/Aire+
(C57BL/6N-Airetm1.1(NCOM)Mfgc/Tcp)
abnormal cholesterol homeostasis J:211773
Airetm1Mand/Aire+
(NOD.129P2-Airetm1Mand)
abnormal chemokine level J:188686
increased CXCL10 level J:188686
Airetm1Ptsn/Airetm1Ptsn
(C.B6-Airetm1Ptsn)
abnormal cytokine level J:174653
Ajap1tm1b(EUCOMM)Hmgu/Ajap1tm1b(EUCOMM)Hmgu
(B6N(Cg)-Ajap1tm1b(EUCOMM)Hmgu/J)
increased circulating alanine transaminase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating chloride level J:211773
increased circulating potassium level J:211773
increased circulating sodium level J:211773
increased circulating total protein level J:211773
Ajubaem1(IMPC)H/Ajubaem1(IMPC)H
(C57BL/6N-Ajubaem1(IMPC)H/H)
increased circulating alkaline phosphatase level J:211773
Ak1tm1Bew/Ak1tm1Bew
(involves: 129P2/OlaHsd * C57BL/6)
abnormal energy expenditure J:66101
abnormal glucose homeostasis J:66101
abnormal nucleotide metabolism J:66101
abnormal response to cardiac infarction J:107843
Ak1tm1Bew/Ak1tm1Bew
Ckmtm1Bew/Ckmtm1Bew

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal nucleotide metabolism J:109659
Akap5tm1.1Jsco/Akap5tm1.1Jsco
(involves: 129S * C57BL/6)
decreased circulating insulin level J:190017
decreased insulin secretion J:190017
improved glucose tolerance J:190017
increased insulin sensitivity J:190017
Akap5tm1Gsm/Akap5tm1Gsm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased circulating insulin level J:190017
homeostasis/metabolism phenotype J:190017
Akap5tm1Jsco/Akap5tm1Jsco
Tg(Ins2-cre)25Mgn/0

(involves: 129S * C57BL/6 * DBA)
decreased circulating insulin level J:190017
impaired glucose tolerance J:190017
increased insulin secretion J:190017
Akap5tm1Mdaq/Akap5tm1Mdaq
(involves: 129 * C57BL/6 * C57BL/6J)
decreased circulating insulin level J:190017
decreased insulin secretion J:190017
improved glucose tolerance J:190017
increased insulin sensitivity J:190017
Akap8Gt(XG068)Byg/Akap8Gt(XG068)Byg
Fignfi/Fignfi

(involves: 129P2/OlaHsd * 129S1/SvImJ * C57BL/6)
cyanosis J:116474
Akap9tm1a(KOMP)Wtsi/Akap9+
(B6JTyr;B6N-Akap9tm1a(KOMP)Wtsi/Wtsi)
decreased circulating calcium level J:175295
decreased circulating cholesterol level J:175295
decreased circulating fructosamine level J:175295
decreased circulating HDL cholesterol level J:175295
decreased circulating LDL cholesterol level J:175295
decreased circulating serum albumin level J:175295
decreased circulating total protein level J:175295
increased circulating fructosamine level J:175295
Akap9tm1a(KOMP)Wtsi/Akap9+
(involves: C57BL/6 * C57BL/6N)
decreased circulating cholesterol level J:213427
decreased circulating glucose level J:213427
decreased circulating HDL cholesterol level J:213427
decreased circulating LDL cholesterol level J:213427
decreased circulating serum albumin level J:213427
decreased circulating total protein level J:213427
increased carbon dioxide production J:213427
increased circulating alkaline phosphatase level J:213427
increased energy expenditure J:213427
increased oxygen consumption J:213427
Akap11tm1.2Jsco/Akap11tm1.2Jsco
(B6.Cg-Akap11tm1.2Jsco)
increased urine osmolality J:234905
Akap13Gt(CSJ306)Byg/Akap13Gt(CSJ306)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal response of heart to induced stress J:231257
Akap13tm1Segj/Akap13tm1Segj
(involves: 129 * C57BL/6)
pericardial effusion J:181087
Akp3tm1Jlm/Akp3tm1Jlm
(involves: 129S2/SvPas * C57BL/6)
abnormal intestinal lipid absorption J:86263
abnormal lipid level J:86263
increased circulating triglyceride level J:86263
Akr1a1Gt(OST222400)Lex/Akr1a1Gt(OST222400)Lex
(B6.129S5-Akr1a1Gt(OST222400)Lex)
abnormal vitamin C level J:164548
aminoaciduria J:164548
Akr1a1tm1Maka/Akr1a1+
(B6.Cg-Akr1a1tm1Maka)
abnormal enzyme/coenzyme activity J:188043
Akr1a1tm1Maka/Akr1a1tm1Maka
(B6.Cg-Akr1a1tm1Maka)
abnormal enzyme/coenzyme activity J:188043
abnormal vitamin C level J:188043
Akr1b3tm1.1Kgab/Akr1b3tm1.1Kgab
(B6.Cg-Akr1b3tm1.1Kgab)
abnormal vitamin C level J:164548
Akr1b3tm1Skc/Akr1b3tm1Skc
(either: B6.129S7-Akr1b3tm1Skc or (involves: 129S7/SvEvBrd * C57BL/6N))
abnormal renal water reabsorption J:77647
decreased urine calcium level J:77647
decreased urine chloride ion level J:77647
decreased urine creatinine level J:77647
decreased urine osmolality J:77647
decreased urine potassium level J:77647
decreased urine sodium level J:77647
decreased urine urea nitrogen level J:77647
homeostasis/metabolism phenotype J:77647
Akr1b3tm1Tona/Akr1b3tm1Tona
(involves: 129S/SvEv * C57BL/6)
decreased urine osmolality J:114187
increased circulating calcium level J:114187
increased circulating magnesium level J:114187
increased urine calcium level J:114187
Akr1b7tm1.1Anm/Akr1b7tm1.1Anm
(involves: 129)
decreased energy expenditure J:208505
decreased respiratory quotient J:208505
homeostasis/metabolism phenotype J:208505
increased circulating adiponectin level J:208505
increased circulating glycerol level J:208505
increased circulating insulin level J:208505
increased circulating leptin level J:208505
increased circulating triglyceride level J:208505
increased liver triglyceride level J:208505
increased susceptibility to diet-induced obesity J:208505
insulin resistance J:208505
Akr1b7tm1.1Fth/Akr1b7tm1.1Fth
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating progesterone level J:123295
increased circulating progesterone level J:123295
Akr1b8tm1.1(KOMP)Vlcg/Akr1b8tm1.1(KOMP)Vlcg
(B6N(Cg)-Akr1b8tm1.1(KOMP)Vlcg/J)
decreased fasting circulating glucose level J:211773
Akr1b8tm1Dgen/Akr1b8tm1Dgen
(Not Specified)
abnormal interferon level J:301852
abnormal interleukin level J:301852
decreased lipogenesis J:301852
increased incidence of tumors by chemical induction J:301852
Akr1c18tm1Mni/Akr1c18tm1Mni
(involves: 129P2/OlaHsd * C57BL/6J)
increased circulating progesterone level J:129608
Akr1d1tm1.1(KOMP)Vlcg/Akr1d1tm1.1(KOMP)Vlcg
(B6N(Cg)-Akr1d1tm1.1(KOMP)Vlcg/J)
decreased fasting circulating glucose level J:211773
Akt1tm1Mbb/Akt1tm1Mbb
(B6.129P2-Akt1tm1Mbb)
decreased susceptibility to diet-induced obesity J:182721
increased basal metabolism J:182721
increased carbon dioxide production J:182721
increased oxygen consumption J:182721
Akt1tm1Nhy/Akt1+
Akt2tm1Rsg/Akt2tm1Rsg

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/1LacJ)
decreased circulating leptin level J:149156
decreased insulin secretion J:149156
hyperglycemia J:149156
impaired glucose tolerance J:149156
increased circulating insulin level J:149156
Akt1tm1Nhy/Akt1+
Akt2tm1Rsg/Akt2tm1Rsg
Akt3tm1Nhy/Akt3tm1Nhy

(involves: 129/Sv * C57BL/6 * DBA/1LacJ)
hyperglycemia J:149156
Akt1tm1Nhy/Akt1+
Akt2tm1Rsg/Akt2tm1Rsg
Ptentm1Ppp/Pten+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/1LacJ)
impaired glucose tolerance J:149156
increased circulating insulin level J:149156
Akt1tm1Nhy/Akt1tm1Nhy
Akt2tm1Rsg/Akt2tm1Rsg

(involves: 129/Sv * C57BL/6 * DBA/1LacJ)
abnormal lipid homeostasis J:83741
Akt1tm1Zzy/Akt1tm1Zzy
Akt3tm1Hem/Akt3tm1Hem
Tg(Myhc-cre)1Xya/0

(involves: 129P2/OlaHsd * FVB)
abnormal physiological response to xenobiotic J:206783
Akt1tm2.1Mbb/Akt1tm2.1Mbb
(involves: 129S4/SvJae * C57BL/6J * FVB/N)
abnormal gluconeogenesis J:182721
abnormal glucose homeostasis J:182721
decreased circulating leptin level J:182721
decreased circulating thyroxine level J:182721
decreased liver triglyceride level J:182721
decreased respiratory quotient J:182721
decreased susceptibility to diet-induced obesity J:182721
improved glucose tolerance J:182721
increased basal metabolism J:182721
increased carbon dioxide production J:182721
increased circulating adiponectin level J:182721
increased fatty acid oxidation J:182721
increased insulin sensitivity J:182721
increased oxygen consumption J:182721
Akt1tm2Mbb/Akt1tm2Mbb
Tg(Ckmm-cre)5Khn/0

(involves: 129S4/SvJae * C57BL/6J * FVB)
homeostasis/metabolism phenotype J:182721
Akt1tm2Mbb/Akt1tm2Mbb
Tg(Nes-cre)1Kln/0

(involves: 129S4/SvJae * C57BL/6J * SJL)
homeostasis/metabolism phenotype J:182721
Akt1s1tm1.1Rrth/Akt1s1tm1.1Rrth
(B6(Cg)-Akt1s1tm1.1Rrth)
increased cerebral infarct size J:231219
increased susceptibility to ischemic brain injury J:231219
Akt2tm1.1Mbb/Akt2+
Lepob/Lepob

(B6.Cg-Lepob Akt2tm1.1Mbb)
decreased liver triglyceride level J:155432
Akt2tm1.1Mbb/Akt2tm1.1Mbb
(involves: 129P2/OlaHsd * C57BL/6)
hyperglycemia J:71491
impaired glucose tolerance J:71491
increased circulating insulin level J:71491
insulin resistance J:71491
Akt2tm1.1Mbb/Akt2tm1.1Mbb
(involves: 129P2/OlaHsd)
decreased liver triglyceride level J:160759
hyperglycemia J:160759
impaired glucose tolerance J:160759
Akt2tm1.1Mbb/Akt2tm1.1Mbb
(B6.129P2-Akt2tm1.1Mbb)
decreased circulating glucose level J:155432
decreased liver triglyceride level J:155432
decreased susceptibility to diet-induced obesity J:155432
increased circulating insulin level J:155432
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Lepob/Lepob

(B6.Cg-Lepob Akt2tm1.1Mbb)
abnormal lipid homeostasis J:155432
decreased circulating cholesterol level J:155432
decreased liver triglyceride level J:155432
increased circulating glucose level J:155432
increased circulating insulin level J:155432
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
hyperglycemia J:160759
impaired glucose tolerance J:160759
Akt2tm1.2Mbb/Akt2tm1.2Mbb
Lepob/Lepob
Tg(Alb1-cre)1Khk/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * SJL)
abnormal lipid homeostasis J:155432
decreased liver triglyceride level J:155432
increased circulating glucose level J:155432
Akt2tm1.2Mbb/Akt2tm1.2Mbb
Tg(Alb1-cre)1Khk/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * SJL)
decreased liver triglyceride level J:155432
Akt2tm1Hem/Akt2tm1Hem
(involves: 129P2/OlaHsd * C57BL/6)
hyperglycemia J:114675
impaired glucose tolerance J:114675
increased circulating insulin level J:114675
insulin resistance J:114675
Akt2tm1Hem/Akt2tm1Hem
(involves: 129P2/OlaHsd)
increased circulating testosterone level J:185012
Akt2tm1Hem/Akt2tm1Hem
Akt3tm1Hem/Akt3tm1Hem

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating testosterone level J:114675
hyperglycemia J:114675
impaired glucose tolerance J:114675
increased circulating insulin level J:114675
insulin resistance J:114675
Akt2tm1Rsg/Akt2tm1Rsg
(DBA/1LacJ-Akt2tm1Rsg)
abnormal glucose homeostasis J:84606
decreased circulating insulin level J:84606
hyperglycemia J:84606
impaired glucose tolerance J:84606
increased circulating insulin level J:84606
insulin resistance J:84606
Akt2tm1Rsg/Akt2tm1Rsg
(involves: C57BL/6 * DBA/1LacJ)
decreased circulating leptin level J:149156
impaired glucose tolerance J:149156
increased circulating insulin level J:149156
insulin resistance J:149156
Akt2tm1Rsg/Akt2tm1Rsg
Akt3tm1Nhy/Akt3tm1Nhy

(involves: 129/Sv * C57BL/6 * DBA/1LacJ)
impaired glucose tolerance J:149156
Akt2tm1Rsg/Akt2tm1Rsg
Ptentm1Ppp/Pten+

(involves: 129S1/Sv * C57BL/6 * DBA/1LacJ)
decreased circulating insulin level J:149156
impaired glucose tolerance J:149156
Akt3tm1Hem/Akt3tm1Hem
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to neuronal excitotoxicity J:98804
Akt3tm1Mbb/Akt3tm1Mbb
(Not Specified)
homeostasis/metabolism phenotype J:96823
Aktiptm1b(EUCOMM)Hmgu/Aktiptm1b(EUCOMM)Hmgu
(C57BL/6N-Aktiptm1b(EUCOMM)Hmgu/Tcp)
increased circulating aspartate transaminase level J:211773
Aladem1(IMPC)Tcp/Alad+
(C57BL/6NCrl-Aladem1(IMPC)Tcp/Tcp)
increased circulating triglyceride level J:211773
Alas2tm1Mym/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal iron level